Cryptococcus gattii infections

Clinical Microbiology Reviews

Volumn 27, Issue 4, 2014, Pages 980-1024

  Chen, Sharon C A ^a,b,c,d   Meyer, Wieland ^a,b,c,e   Sorrell, Tania C ^a,b,c  

^a University of Sydney   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d Institute of Clinical Microbiology and Medical Research   (Australia)

^e WESTMEAD HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; CENTRAL NERVOUS SYSTEM INFECTION; CRYPTOCOCCUS GATTII; CRYPTOCOCCUS NEOFORMANS; FUNGAL VIRULENCE; GEOGRAPHIC DISTRIBUTION; HUMAN; IMMUNE RESPONSE; INCUBATION TIME; LUNG DISEASE; MICROBIAL DIVERSITY; MICROBIOLOGY; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MYCOSIS; NONHUMAN; PATHOGENESIS; PHYLOGENY; POLYMERASE CHAIN REACTION; TAXONOMY; TRANSCRIPTOMICS; ANIMAL; CLASSIFICATION; COMPLICATION; CRYPTOCOCCOSIS; DRUG EFFECTS; PATHOGENICITY; PHYSIOLOGY;

CRYPTOCOCCUS GATTII;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS GATTII; HUMANS;

EID: 84907780591     PISSN: 08938512     EISSN: 10986618     Source Type: Journal    
DOI: 10.1128/CMR.00126-13     Document Type: Article

References (406)

1. Fraser JA, Giles SS, Wenink EC, Geunes-Boyer SG, Wright JR, Diezmann S, Allen A, Stajich JE, Dietrich FS, Perfect JR, Heitman J. 2005. Same-sex mating and the origin of the Vancouver Island Cryptococcus gattii outbreak. Nature 437:1360–1364. http://dx.doi.org/10.1038/nature04220.
2. Kwon-Chung KJ, Bennett JE, Theodore TS. 1978. Cryptococcus bacil-lisporus sp. nov.: serotype B-C of Cryptococcus neoformans. Int. J. Syst. Bacteriol. 28:616–620. http://dx.doi.org/10.1099/00207713-28-4-616.
3. Findley K, Sun S, Fraser JA, Hsueh YP, Averette AF, Li W, Dietrich FS, Heitman J. 2012. Discovery of a modified tetrapolar sexual cycle in Cryptococcus amylolentus and the evolution of MAT in the Cryptococcus species complex. PLoS Genet. 8:e1002528. http://dx.doi.org/10.1371/journal.pgen.1002528.
4. Fell JW, Boekhout T, Fonseca A, Scorzetti G, Statzell-Tallman A. 2000. Biodiversity and systematics of basidiomycetous yeasts as determined by large-subunit rDNA D1/D2 domain sequence analysis. Int. J. Syst. Evol. Microbiol. 50(Part 3):1351–1371. http://dx.doi.org/10.1099/00207713-50-3-1351.
5. Sanfelice F. 1895. Ueber einen neuen pathogenen Blastomyceten welcher innerhalb der Gewebe unter Bildung kalkartig aussehender Mas-sen degeneriert. Zentralbl. Bakteriol. Parasit. Infect. Hyg. 18:521–526.
6. Vuilemin P. 1901. Les blastomycetes pathogens. Rev. Gen. Sci. Pures Appl. 12:732–751.
7. Weis JD. 1902. Four pathogenic torulae (Blastomycetes). J. Med. Res. 7:280–311.
8. Stoddard JL, Cutler EC. 1916. Torula infection in man. Rockefeller Inst. Med. Res. Monogr. 6:1098.
9. Todd RL, Herrmann WW. 1936. The life cycle of the organism causing yeast meningitis. J. Bacteriol. 32:89–97.
10. Benham RW. 1935. Cryptococci: their identification by morphology and serology. J. Infect. Dis. 57:255–274. http://dx.doi.org/10.1093/infdis/57.3.255.
11. Benham RW. 1950. Cryptococcosis and blastomycosis. Ann. N. Y. Acad. Sci. 50:1299–1314. http://dx.doi.org/10.1111/j.1749-6632.1950.tb39828.x.
12. Buschke A. 1895. Ueber eine durch Coccidien hervorgerufene Krankheit des Menschen. Dtsch. Med. Wochenschr. 21:14.
13. Busse O. 1895. Ueber parasitaere Zelleinschluesse und ihre Zuechtung. Zentralbl. Bakteriol. 16:175–180.
14. Sanfelice F. 1894. Contributo alla morfologia e biologia dei blastomiceti che si sviluppano nei succhi di alcuni frutti. Ann. Igiene 4:463–495.
15. Evans EE. 1949. An immunologic comparison of twelve strains of Cryp-tococcus neoformans (Torula histolytica). Proc. Soc. Exp. Biol. Med. 71: 644–646. http://dx.doi.org/10.3181/00379727-71-17283.
16. Vogel RA. 1966. The indirect fluorescent antibody test for the detection of antibody in human cryptococcal disease. J. Infect. Dis. 116:573–580. http://dx.doi.org/10.1093/infdis/116.5.573.
17. Vanbreuseghem R, Takashio M. 1970. An atypical strain of Cryptococcus neoformans (Sanfelice) Vuillemin, 1895, II. Cryptococcus neoformans var. gattii var. nov. Ann. Soc. Belg. Med. Trop. 50:692–702.
18. Curtis F. 1896. Contribution à l’étude de la saccharomycose humaine. Ann. Inst. Pasteur (Paris) 10:449–468.
19. Kwon-Chung KJ, Boekhout T, Fell JW, Diaz M. 2002. Proposal to conserve the name Cryptococcus gattii against C. hondurianus and C. bacillisporus (Basidiomycota, Hymenomycetes, Tremellomycetidae). Taxon 51:804–806. http://dx.doi.org/10.2307/1555045.
20. Kwon-Chung KJ. 1975. A new genus, Filobasidiella, the perfect state of Cryptococcus neoformans. Mycologia 67:1197–1200. http://dx.doi.org/10.2307/3758842.
21. Kwon-Chung KJ. 1976. Morphogenesis of Filobasidiella neoformans, the sexual state of Cryptococcus neoformans. Mycologia 68:821–833. http://dx.doi.org/10.2307/3758800.
22. Kwon-Chung KJ. 1976. A new species of Filobasidiella, the sexual state of Cryptococcus neoformans B and C serotypes. Mycologia 68:943–946.
23. Kwon-Chung KJ, Polacheck I, Bennett JE. 1982. Improved diagnostic medium for separation of Cryptococcus neoformans var. neoformans (serotypes A and D) and Cryptococcus neoformans var. gattii (serotypes B and C). J. Clin. Microbiol. 15:535–537.
24. Aulakh HS, Straus SE, Kwon-Chung KJ. 1981. Genetic relatedness of Filobasidiella neoformans (Cryptococcus neoformans) and Filobasidiella bacilispora (Cryptococcus bacillisporus). Int. J. Syst. Bacteriol. 31:97–103. http://dx.doi.org/10.1099/00207713-31-1-97.
25. Ellis DH. 1987. Cryptococcus neoformans var. gattii in Australia. J. Clin. Microbiol. 25:430–431.
26. Ellis D., Pfeiffer TJ. 1990. Natural habitat of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 28:1642–1644.
27. Mitchell DH, Sorrell TC, Allworth AM, Heath CH, McGregor AR, Papanaoum K, Richards MJ, Gottlieb T. 1995. Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcome. Clin. Infect. Dis. 20:611–616. http://dx.doi.org/10.1093/clinids/20.3.611.
28. Speed B, Dunt D. 1995. Clinical and host differences between infections with the two varieties of Cryptococcus neoformans. Clin. Infect. Dis. 21: 28–34; discussion 35–36. http://dx.doi.org/10.1093/clinids/21.1.28.
29. Chen S, Sorrell T, Nimmo G, Speed B, Currie B, Ellis D, Marriott D, Pfeiffer T, Parr D, Byth K, Australasian Cryptococcal Study Group. 2000. Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand. Clin. Infect. Dis. 31:499–508. http://dx.doi.org/10.1086/313992.
30. Fan M, Chen LC, Ragan MA, Gutell RR, Warner JR, Currie B., Casadevall A. 1995. The 5S rRNA and the rRNA intergenic spacer of the two varieties of Cryptococcus neoformans. J. Med. Vet. Mycol. 33:215–221. http://dx.doi.org/10.1080/02681219580000451.
31. Diaz M., Boekhout T, Theelen B, Fell JW. 2000. Molecular sequence analyses of the intergenic spacer (IGS) associated with rDNA of the two varieties of the pathogenic yeast, Cryptococcus neoformans. Syst. Appl. Mi-crobiol. 23:535–545. http://dx.doi.org/10.1016/S0723-2020(00)80028-4.
32. Xu J, Vilgalys R, Mitchell TG. 2000. Multiple gene genealogies reveal recent dispersion and hybridization in the human pathogenic fungus Cryptococcus neoformans. Mol. Ecol. 9:1471–1481. http://dx.doi.org/10.1046/j.1365-294x.2000.01021.x.
33. Boekhout T, Theelen B, Diaz M, Fell JW, Hop WC, Abeln EC, Dromer F, Meyer W. 2001. Hybrid genotypes in the pathogenic yeast Cryptococ-cus neoformans. Microbiology 147:891–907.
34. Meyer W, Mitchell TG, Freedman EZ, Vilgalys R. 1993. Hybridization probes for conventional DNAfingerprinting used assingle primers inthe polymerase chain reaction to distinguish strains of Cryptococcus neofor-mans. J. Clin. Microbiol. 31:2274–2280.
35. Meyer W, Mitchell TG. 1995. Polymerase chain reaction fingerprinting in fungi using single primers specific to minisatellites and simple repetitive DNA sequences: strain variation in Cryptococcus neoformans. Elec-trophoresis 16:1648–1656. http://dx.doi.org/10.1002/elps.11501601273.
36. D’Souza CA, Kronstad J., Taylor G, Warren R, Yuen M, Hu G, Jung WH, Sham A, Kidd SE, Tangen K, Lee N, Zeilmaker T, Sawkins J, McVicker G, Shah S, Gnerre S, Griggs A, Zeng Q, Bartlett K, Li W, Wang X, Heitman J, Stajich JE, Fraser JA, Meyer W, Carter D, Schein J, Krzywinski M, Kwon-Chung KJ, Varma A, Wang J, Brunham R, Fyfe M, Ouellette BF, Siddiqui A, Marra M, Jones S, Holt R, Birren BW, Galagan JE, Cuomo CA. 2011. Genome variation in Cryptococcus gattii, an emerging pathogen of immunocompetent hosts. mBio 2(1): e00342-10. http://dx.doi.org/10.1128/mBio.00342-10.
37. Stephen C, Lester S, Black W, Fyfe M, Raverty S. 2002. Multispecies outbreak of cryptococcosis on southern Vancouver Island, British Columbia. Can. Vet. J. 43:792–794.
38. Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W. 2004. A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc. Natl. Acad. Sci. U. S. A. 101:17258–17263. http://dx.doi.org/10.1073/pnas.0402981101.
39. Byrnes EJ, Bartlett KH, Perfect JR, Heitman J. 2011. Cryptococcus gattii: an emerging fungal pathogen infecting humans and animals. Microbes Infect. 13:895–907. http://dx.doi.org/10.1016/j.micinf.2011.05.009.
40. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E, Ibero-American Cryptococcal Study Group. 2003. Molecular typing of Ibero-American Cryptococcus neoformans isolates. Emerg. Infect. Dis. 9:189–195. http://dx.doi.org/10.3201/eid0902.020246.
41. Latouche GN, Huynh M, Sorrell TC, Meyer W. 2003. PCR-restriction fragment length polymorphism analysis of the phospho-lipase B (PLB1) gene for subtyping of Cryptococcus neoformans isolates. Appl. Environ. Microbiol. 69:2080–2086. http://dx.doi.org/10.1128/AEM.69.4.2080-2086.2003.
42. Hanafy A, Kaocharoen S, Jover-Botella A, Katsu M, Iida S, Kogure T, Gonoi T, Mikami Y, Meyer W. 2008. Multilocus microsatellite typing for Cryptococcus neoformans var. grubii. Med. Mycol. 46:685–696. http://dx.doi.org/10.1080/13693780802027062.
43. Meyer W, Aanensen DM, Boekhout T, Cogliati M, Diaz M., Esposto MC, Fisher M, Gilgado F, Hagen F, Kaocharoen S, Litvintseva AP, Mitchell TG, Simwami SP, Trilles L, Viviani MA, Kwon-Chung J. 2009. Consensus multi-locus sequence typing scheme for Cryptococcus neoformans and Cryptococcus gattii. Med. Mycol. 47:561-570. http://dx.doi.org/10.1080/13693780902953886.
44. Bovers M, Hagen F, Kuramae EE, Diaz M., Spanjaard L, Dromer F, Hoogveld HL, Boekhout T. 2006. Unique hybrids between the fungal pathogens Cryptococcus neoformans and Cryptococcus gattii. FEMS Yeast Res. 6:599–607. http://dx.doi.org/10.1111/j.1567-1364.2006.00082.x.
45. Bovers M, Hagen F, Kuramae EE, Hoogveld HL, Dromer F, St-Germain G, Boekhout T. 2008. AIDS patient death caused by novel Cryptococcus neoformans X C. gattii hybrid. Emerg. Infect. Dis. 14:1105-1108. http://dx.doi.org/10.3201/eid1407.080122.
46. Ngamskulrungroj P, Gilgado F, Faganello J, Litvintseva AP, Leal AL, Tsui KM, Mitchell TG, Vainstein MH, Meyer W. 2009. Genetic diversity of the Cryptococcus species complex suggests that Cryptococcus gattii deserves to have varieties. PLoS One 4:e5862. http://dx.doi.org/10.1371/journal.pone.0005862.
47. Sharpton TJ, Neafsey DE, Galagan JE, Taylor JW. 2008. Mechanisms of intron gain and loss in Cryptococcus. Genome Biol. 9:R24. http://dx.doi.org/10.1186/gb-2008-9-1-r24.
48. Meyer W, Gilgado F, Ngamskulrungroj P, Trilles L, Hagen F, Cas-taneda E, Boekhout T. 2011. Molecular typing of the Cryptococcus neoformans/Cryptococcus gattii species complex, p 327-357. In Heitman J, KozelTR, Kwon-ChungKJ, Perfect JR, CasadevallA. (ed), Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.
49. Bovers M, Hagen F, Kuramae EE, Boekhout T. 2008. Six monophyletic lineages identified within Cryptococcus neoformans and Cryptococcus gat-tii by multi-locus sequence typing. Fungal Genet. Biol. 45:400–421. http://dx.doi.org/10.1016/j.fgb.2007.12.004.
50. Bovers M, Hagen F, Kuramae EE, Boekhout T. 2009. Promiscuous mitochondria in Cryptococcus gattii. FEMS Yeast Res. 9:489–503. http://dx.doi.org/10.1111/j.1567-1364.2009.00494.x.
51. Gillece JD, Schupp JM, Balajee SA, Harris J, Pearson T, Yan Y, Keim P, DeBess E, Marsden-Haug N, Wohrle R, Engelthaler DM, Lockhart SR. 2011. Whole genome sequence analysis of Cryptococcus gattii from the Pacific Northwest reveals unexpected diversity. PLoS One 6:e28550. http://dx.doi.org/10.1371/journal.pone.0028550.
52. Hagen F, Ceresini PC, Polacheck I, Ma H, van Nieuwerburgh F, Gabaldon T, Kagan S, Pursall ER, Hoogveld HL, van Iersel LJ, Klau GW, Kelk SM, Stougie L, Bartlett KH, Pryszcz KLP, Castaneda E, Lazera M, Meyer W, Deforce D, Meis JF, May RC, Klaassen CH, Boekhout T. 2013. Ancient dispersal of the human fungal pathogen Cryptococcus gattii from the Amazon rainforest. PLoS One 8:e71148. http://dx.doi.org/10.1371/journal.pone.0071148.
53. Engelthaler DM, Hicks ND, Gillece JD, Roe CC, Schupp JM, Driebe EM, Gilgado F, Carriconde F, Trilles L, Firacative C, Ngamskulrungroj P, Castañeda E, dos Santos Lazera M, Melhem MS., Pérez-Bercoff A, Huttley G, Sorrell TC, Voelz K, May RC, Fisher MC, Thompson GR, Lockhart SR, Keim P, Meyer W. 2014. Cryptococcus gattii in North American Pacific Northwest: whole-population genome analysis provides insights into species evolution and dispersal. mBio 5(4):e01464-14. http://dx.doi.org/10.1128/mBio.01464-14.
54. Billmyre RB, Croll D, Lin W, Mieczkowski P, Carter D., Cuomo CA, Kronstad J., Heitman J. 2014. Highly recombinant VGII Cryptococcus gattii population develops clonal outbreak clusters through both sexual macroevolution and asexual microevolution. mBio 5(4):e01494-14. http://dx.doi.org/10.1128/mBio.01494-14.
55. Trilles L, Wang B, Firacative C, dos Santos Lazéra M, Wanke B, Meyer W. 2014. Identification of the major molecular types of Cryptococcus neoformans and Cryptococcus gattii by hyperbranched rolling circle amplification. PLoS One 9:e0094648. http://dx.doi.org/10.1371/journal.pone.0094648.
56. Firacative C, Trilles L, Meyer W. 2012. MALDI-TOF MS enables the rapid identification of the major molecular types within the Cryptococcus neoformans/C. gattii species complex. PLoS One 7:e37566. http://dx.doi.org/10.1371/journal.pone.0037566.
57. Posteraro B, Vella A, Cogliati M, De Carolis E, Florio AR, Posteraro P, Sanguinetti M, Tortorano AM. 2012. Matrix-assisted laser desorp-tion ionization-time of flight mass spectrometry-based method for discrimination between molecular types of Cryptococcus neoformans and Cryptococcus gattii. J. Clin. Microbiol. 50:2472–2476. http://dx.doi.org/10.1128/JCM.00737-12.
58. Boekhout T, van Belkum A. 1997. Variability of karyotypes and RAPD types in genetically related strains of Cryptococcus neoformans. Curr. Genet. 32:203–208. http://dx.doi.org/10.1007/s002940050267.
59. Ruma P, Chen S., Sorrell TC, Brownlee AG. 1996. Characterization of Cryptococcus neoformans by random DNA amplification. Lett. Appl. Microbiol. 23:312–316. http://dx.doi.org/10.1111/j.1472-765X.1996.tb00197.x.
60. Williams JG, Kubelik AR, Livak KJ, Rafalski JA, Tingey SV. 1990. DNA polymorphisms amplified by arbitrary primers are useful as genetic markers. Nucleic Acids Res. 18:6531–6535. http://dx.doi.org/10.1093/nar/18.22.6531.
61. Mitchell TG, Sandin RL, Bowman BH, Meyer W, Merz WG. 1994. Molecular mycology: probes and applications of PCR technology. J. Med. Vet. Mycol. 32(Suppl 1):S351–S366.
62. Ellis D, Marriott D, Hajjeh RA, Warnock D, Meyer W, Barton R. 2000. Epidemiology: surveillance of fungal infections. Med. Mycol. 38:173–182. http://dx.doi.org/10.1080/mmy.38.s1.173.182.
63. Bovers M, Hagen F, Boekhout T. 2008. Diversity of the Cryptococcus neoformans-Cryptococcus gattii species complex. Rev. Iberoam. Micol. 25:S4–S12. http://dx.doi.org/10.1016/S1130-1406(08)70019-6.
64. Tautz D, Renz M. 1984. Simple sequences are ubiquitous repetitive components of eukaryotic genomes. Nucleic Acids Res. 12:4127–4138. http://dx.doi.org/10.1093/nar/12.10.4127.
65. Karaoglu H, Lee CMY, Meyer W. 2005. Survey of simple sequence repeats in completed fungal genomes. Mol. Biol. Evol. 22:639–649. http://dx.doi.org/10.1093/molbev/msi057.
66. Karaoglu H, Lee CMY, Carter D, Meyer W. 2008. Development of polymorphic microsatellite markers for Cryptococcus neoformans. Mol. Ecol. Resour. 8:1136–1138. http://dx.doi.org/10.1111/j.1755-0998.2008.02196.x.
67. Byrnes EJ, Bildfell RJ, Frank SA, Mitchell TG, Marr K., Heitman J. 2009. Molecular evidence that the range of the Vancouver Island outbreak of Cryptococcus gattii infection has expanded into the Pacific Northwest in the United States. J. Infect. Dis. 199:1081–1086. http://dx.doi.org/10.1086/597306.
68. Byrnes EJ, Li W, Lewit Y, Ma H, Voelz K, Ren P, Carter D., Chaturvedi V, Bildfell RJ, May RC, Heitman J. 2010. Emergence and pathogenicity of highly virulent Cryptococcus gattii genotypes in the northwest United States. PLoS Pathog. 6:e1000850. http://dx.doi.org/10.1371/journal.ppat.1000850.
69. Aminnejad M, Diaz M, Arabatzis M, Castaneda E, Lazera M, Velegraki A, Marriott D, Sorrell TC, Meyer W. 2012. Identification of novel hybrids between Cryptococcus neoformans var. grubii VNI and Cryptococ-cus gattii VGII. Mycopathologia 173:337–346. http://dx.doi.org/10.1007/s11046-011-9491-x.
70. Kwon-Chung KJ, Bennett JE. 1984. Epidemiologic differences between the two varieties ofCryptococcus neoformans. Am. J.Epidemiol. 120:123–130.
71. Casali AK, Goulart L, Rosa e Silva LK, Ribeiro AM, Amaral AA, Alves SH, Schrank A, Meyer W, Vainstein MH. 2003. Molecular typing of clinical and environmental Cryptococcus neoformans isolates in the Brazilian state Rio Grande do Sul. FEMS Yeast Res. 3:405–415. http://dx.doi.org/10.1016/S1567-1356(03)00038-2.
72. Trilles L, Lazera M, Wanke B, Theelen B, Boekhout T. 2003. Genetic characterization of environmental isolates of the Cryptococcus neofor-mans species complex from Brazil. Med. Mycol. 41:383–390. http://dx.doi.org/10.1080/1369378031000137206.
73. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E. 2006. Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res. 6:625–635. http://dx.doi.org/10.1111/j.1567-1364.2006.00055.x.
74. Chen J, Varma A, Diaz M., Litvintseva AP, Wollenberg KK, Kwon-Chung KJ. 2008. Cryptococcus neoformans strains and infection in apparently immunocompetent patients, China. Emerg. Infect. Dis. 14:755–762. http://dx.doi.org/10.3201/eid1405.071312.
75. Feng X, Yao Z, Ren D, Liao W. 2008. Simultaneous identification of molecular and mating types within the Cryptococcus species complex by PCR-RFLP analysis. J. Med. Microbiol. 57:1481–1490. http://dx.doi.org/10.1099/jmm.0.2008/003665-0.
76. Feng X, Yao Z, Ren D, Liao W, Wu J. 2008. Genotype and mating type analysis of Cryptococcus neoformans and Cryptococcus gattii isolates from China that mainly originated from non-HIV-infected patients. FEMS Yeast Res. 8:930–938. http://dx.doi.org/10.1111/j.1567-1364.2008.00422.x.
77. Trilles L, dos Santos Lazera M, Wanke B, Oliveira RV, Barbosa GG, Nishikawa MM, Morales BP, Meyer W. 2008. Regional pattern of the molecular types of Cryptococcus neoformans and Cryptococcus gattii in Brazil. Mem. Inst. Oswaldo Cruz 103:455–462. http://dx.doi.org/10.1590/S0074-02762008000500008.
78. Olivares LR, Martinez KM, Cruz RM, Rivera MA, Meyer W, Espinosa RA, Martinez R., Santos GM. 2009. Genotyping of Mexican Cryptococ-cus neoformans and C. gattii isolates by PCR-fingerprinting. Med. Mycol. 47:713–721. http://dx.doi.org/10.3109/13693780802559031.
79. Meyer W, Trilles L. 2010. Genotyping of the Cryptococcus neoformans/C. gattii species complex. Aust. Biochem. 41:11–15.
80. Cogliati M, Chandrashekar N, Esposto MC, Chandramuki A, Petrini B, Viviani MA. 2012. Cryptococcus gattii serotype-C strains isolated in Bangalore, Karnataka, India. Mycoses 55:262–268. http://dx.doi.org/10.1111/j.1439-0507.2011.02082.x.
81. Byrnes EJ, Bildfell RJ, Dearing PL, Valentine BA, Heitman J. 2009. Cryptococcus gattii with bimorphic colony types in a dog in western Oregon: additional evidence for expansion of the Vancouver Island outbreak. J. Vet. Diagn. Invest. 21:133–136. http://dx.doi.org/10.1177/104063870902100122.
82. Lockhart SR, Iqbal N, Harris J., Grossman NT, DeBess E, Wohrle R, Marsden-Haug N, Vugia DJ. 2013. Cryptococcus gattii in the United States: genotypic diversity of human and veterinary isolates. PLoS One 8:e74737. http://dx.doi.org/10.1371/journal.pone.0074737.
83. Byrnes EJ, Li W, Ren P, Lewit Y, Voelz K, Fraser JA, Dietrich FS, May RC, Chaturvedi S, Chaturvedi V, Heitman J. 2011. A diverse population of Cryptococcus gattii molecular type VGIII in southern Californian HIV/AIDS patients. PLoS Pathog. 7:e1002205. http://dx.doi.org/10.1371/journal.ppat.1002205.
84. Byrnes EJ, Marr KA. 2011. The outbreak of Cryptococcus gattii in western North America: epidemiology and clinical issues. Curr. Infect. Dis. Rep. 13:256–261. http://dx.doi.org/10.1007/s11908-011-0181-0.
85. MacDougall L, Kidd SE, Galanis E, Mak S, Leslie MJ, Cieslak PR, Kronstad J., Morshed M., Bartlett KH. 2007. Spread of Cryptococcus gattii in British Columbia, Canada, and detection in the Pacific Northwest, USA. Emerg. Infect. Dis. 13:42–50. http://dx.doi.org/10.3201/eid1301.060827.
86. Meyer W. 2007. The emergence of Cryptococcus gattii VGII as a super killer? Microbiol. Aust. 5:70–71.
87. Carriconde F, Gilgado F, Arthur I, Ellis D, Malik R, van de Wiele N, Robert V, Currie B., Meyer W. 2011. Clonality and alpha-a recombination in the AustralianCryptococcus gattii VGII population—an emerging outbreak in Australia. PLoS One 6:e16936. http://dx.doi.org/10.1371/journal.pone.0016936.
88. Kaocharoen S, Ngamskulrungroj P, Firacative C, Trilles L, Piyabong-karn D, Banlunara W, Poonwan N, Chaiprasert A, Meyer W, Chin-damporn A. 2013. Molecular epidemiology reveals genetic diversity amongst isolates of the Cryptococcus neoformans/C. gattii species complex in Thailand. PLoS Negl. Trop. Dis. 7:e2297. http://dx.doi.org/10.1371/journal.pntd.0002297.
89. Lazera M., Salmito Cavalcanti MA, Londero AT, Trilles L, Nishikawa MM, Wanke B. 2000. Possible primary ecological niche of Cryptococcus neoformans. Med. Mycol. 38:379–383. http://dx.doi.org/10.1080/mmy.38.5.379.383.
90. Hagen F, Colom MF, Swinne D, Tintelnot K, Iatta R, Montagna MT, Torres-Rodriguez JM, Cogliati M, Velegraki A, Burggraaf A, Kamer-mans A, Sweere JM, Meis JF, Klaassen CH, Boekhout T. 2012. Autochthonous and dormant Cryptococcus gattii infections in Europe. Emerg. Infect. Dis. 18:1618–1624. http://dx.doi.org/10.3201/eid1810.120068.
91. Baro T, Torres-Rodriguez JM, De Mendoza MH, Morera Y, Alia C. 1998. First identification of autochthonous Cryptococcus neoformans var. gattii isloated from goats with predominantly severe pulmonary disease in Spain. J. Clin. Microbiol. 36:458–461.
92. Levy R, Pitout J, Long P, Gill MJ. 2007. Late presentation of Crypto-coccus gattii meningitis in a traveller to Vancouver Island: a case report. Can. J. Infect. Dis. Med. Microbiol. 18:197–199.
93. Lindberg J, Hagen F, Laursen A, Stenderup J, Boekhout T. 2007. Cryptococ-cus gattii risk for tourists visiting Vancouver Island, Canada. Emerg. Infect. Dis. 13:178–179. http://dx.doi.org/10.3201/eid1301.060945.
94. Georgi A, Schneemann M, Tintelnot K, Calligaris-Maibach RC, Meyer S, Weber R, Bosshard PP. 2009. Cryptococcus gattii meningoencepha-litisinan immunocompetent person13months after exposure. Infection 37:370–373. http://dx.doi.org/10.1007/s15010-008-8211-z.
95. Steele KT, Thakur R, Nthobatsang R, Steenhoff AP, Bisson GP. 2010. In-hospital mortality of HIV-infected cryptococcal meningitis patients with C. gattii and C. neoformans infection in Gaborone, Botswana. Med. Mycol. 48:1112–1115. http://dx.doi.org/10.3109/13693781003774689.
96. Litvintseva AP, Thakur R, Reller LB, Mitchell TG. 2005. Prevalence of clinical isolates of Cryptococcus gattii serotype C among patients with AIDS in sub-Saharan Africa. J. Infect. Dis. 192:888–892. http://dx.doi.org/10.1086/432486.
97. Morgan J, McCarthy KM, Gould S, Fan K, Arthington-Skaggs B, Iqbal N, Stamey K, Hajjeh RA, Brandt ME, Gauteng Cryptococcal Surveillance Initiative Group. 2006. Cryptococcus gattii infection: characteristics and epidemiologyof cases identifiedinaSouth African province with high HIV seroprevalence, 2002-2004. Clin. Infect. Dis. 43:1077–1080. http://dx.doi.org/10.1086/507897.
98. Sorrell TC, Chen S., Ruma P, Meyer W, Pfeiffer T., Ellis D., Brownlee AG. 1996. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. gattii by random amplification of polymorphic DNA analysis and PCR fingerprinting. J. Clin. Microbiol. 34: 1253–1260.
99. Sorrell TC, Brownlee AG, Ruma P, Malik R, Pfeiffer T., Ellis DH. 1996. Natural environmental sources of Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 34:1261–1263.
100. Pfeiffer T., Ellis DH. 1992. Environmental isolation of Cryptococcus neoformans var. gattii from Eucalyptus tereticornis. J. Med. Vet. Mycol. 30:407–408. http://dx.doi.org/10.1080/02681219280000541.
101. Ellis D., Pfeiffer T.. 1990. Ecology, life cycle, and infectious propagule of Cryptococcus neoformans. Lancet 336:923–925. http://dx.doi.org/10.1016/0140-6736(90)92283-N.
102. Pfeiffer T, Ellis D. 1991. Environmental isolation of Cryptococcus neo-formans gattii from California. J. Infect. Dis. 163:929–930. http://dx.doi.org/10.1093/infdis/163.4.929.
103. Kidd SE, Bach PJ, Hingston AO, Mak S, Chow Y, MacDougall L, Kronstad J., Bartlett KH. 2007. Cryptococcus gattii dispersal mechanisms, British Columbia, Canada. Emerg. Infect. Dis. 13:51–57. http://dx.doi.org/10.3201/eid1301.060823.
104. Madrenys N, De Vroey C, Raes-Wuytack C, Torres-Rodriguez JM. 1993. Identification of the perfect state of Cryptococcus neoformans from 195 clinical isolates including 84 from AIDS patients. Mycopathologia 123:65–68. http://dx.doi.org/10.1007/BF01365081.
105. Colom MF, Frases S, Ferrer C, Jover A, Andreu M, Reus S, Sanchez M, Torres-Rodriguez JM. 2005. First case of human cryptococcosis due to Cryptococcus neoformans var. gattii in Spain. J. Clin. Microbiol. 43:3548–3550. http://dx.doi.org/10.1128/JCM.43.7.3548-3550.2005.
106. Fortes ST, Lazera M., Nishikawa MM, Macedo RC, Wanke B. 2001. First isolation of Cryptococcus neoformans var. gattii from a native jungle tree in the Brazilian Amazon rainforest. Mycoses 44:137–140. http://dx.doi.org/10.1046/j.1439-0507.2001.00651.x.
107. Grover N, Nawange SR, Naidu J, Singh SM, Sharma A. 2007. Ecological niche of Cryptococcus neoformans var. grubii and Cryptococcus gattii in decaying wood of trunk hollows of living trees in Jabalpur City of central India. Mycopathologia 164:159–170. http://dx.doi.org/10.1007/s11046-007-9039-2.
108. Hagen F, Boekhout T. 2010. The search for the natural habitat of Cryp-tococcus gattii. Mycopathologia 170:209–211. http://dx.doi.org/10.1007/s11046-010-9313-6.
109. Mitchell TG, Castaneda E, Nielson K, Wanke B, dos Santos Lazera M. 2011. Environmental niches for Cryptococcus neoformans and Cryptococ-cus gattii, p 237–260. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from pathogen to model yeast. ASM Press, Washington, DC.
110. Mahmoud YA. 2000. First environmental isolation of Cryptococ-cus neoformans var. neoformans and var. gatti from the Gharbia Gover-norate, Egypt. Mycopathologia 148:83–86. http://dx.doi.org/10.1023/A:1007166818993.
111. Mseddi F, Sellami A, Jarboui MA, Sellami H, Makni F, Ayadi A. 2011. First environmental isolations of Cryptococcus neoformans and Crypto-coccus gattii in Tunisia and review of published studies on environmental isolations in Africa. Mycopathologia 171:355–360. http://dx.doi.org/10.1007/s11046-010-9381-7.
112. Chen S., Currie B., Campbell HM, Fisher DA, Pfeiffer T., Ellis D., Sorrell TC. 1997. Cryptococcus neoformans var. gattii infection in northern Australia: existence of an environmental source other than known host eucalypts. Trans. R. Soc. Trop. Med. Hyg. 91:547–550. http://dx.doi.org/10.1016/S0035-9203(97)90021-3.
113. Halliday C., Carter DA. 2003. Clonal reproduction and limited dispersal inan environmental population ofCryptococcus neoformans var. gattii isolates from Australia. J. Clin. Microbiol. 41:703–711. http://dx.doi.org/10.1128/JCM.41.2.703-711.2003.
114. Kidd SE, Sorrell TC, Meyer W. 2003. Isolation of two molecular types of Cryptococcus neoformans var. gattii from insect frass. Med. Mycol. 41: 171–176. http://dx.doi.org/10.1080/mmy.41.2.171.176.
115. Campbell LT, Currie B., Krockenberger M, Malik R, Meyer W, Heit-man J, Carter D. 2005. Clonality and recombination in genetically differentiated subgroups ofCryptococcus gattii. Eukaryot. Cell 4:1403–1409. http://dx.doi.org/10.1128/EC.4.8.1403-1409.2005.
116. Campbell LT, Fraser JA, Nichols CB, Dietrich FS, Carter D, Heitman J. 2005. Clinical and environmental isolates of Cryptococcus gattii from Australia that retain sexual fecundity. Eukaryot. Cell 4:1410–1419. http://dx.doi.org/10.1128/EC.4.8.1410-1419.2005.
117. Saul N, Krockenberger M, Carter D. 2008. Evidence of recombination in mixed-mating-type and alpha-only populations of Cryptococcus gattii sourced from single eucalyptus tree hollows. Eukaryot. Cell 7:727–734. http://dx.doi.org/10.1128/EC.00020-08.
118. Colom MF, Hagen F, Gonzalez A, Mellado A, Morera N, Linares C, Garcia DF, Penataro JS, Boekhout T, Sanchez M. 2012. Ceratonia siliqua (carob) trees as natural habitat and source of infection by Cryp-tococcus gattiiin the Mediterranean environment. Med. Mycol. 50:67–73. http://dx.doi.org/10.3109/13693786.2011.574239.
119. Campisi E, Mancianti F, Pini G, Faggi E, Gargani G. 2003. Investigation in central Italy of the possible association between Cryptococcus neo-formans var. gattii and Eucalyptus camaldulensis. Eur. J. Epidemiol. 18: 357–362. http://dx.doi.org/10.1023/A:1023652920595.
120. Kidd SE, Chow Y, Mak S, Bach PJ, Chen H, Hingston AO, Kronstad J., Bartlett KH. 2007. Characterization of environmental sources of the human and animal pathogen Cryptococcus gattii in British Columbia, Canada, and the Pacific Northwest of the United States. Appl. Environ. Microbiol. 73:1433–1443. http://dx.doi.org/10.1128/AEM.01330-06.
121. Springer DJ, Chaturvedi V. 2010. Projecting global occurrence of Cryp-tococcus gattii. Emerg. Infect. Dis. 16:14–20. http://dx.doi.org/10.3201/eid1601.090369.
122. Botes A, Boekhout T, Hagen F, Vismer H, Swart J, Botha A. 2009. Growth and mating of Cryptococcus neoformans var. grubii on woody debris. Microb. Ecol. 57:757–765. http://dx.doi.org/10.1007/s00248-008-9452-1.
123. Xue C, Tada Y, Dong X, Heitman J. 2007. The human fungal pathogen Cryptococcus can complete its sexual cycle during a pathogenic association with plants. Cell Host Microbe 1:263–273. http://dx.doi.org/10.1016/j.chom.2007.05.005.
124. Springer DJ, Ren P, Raina R, Dong Y, Behr MJ, McEwen BF, Bowser SS, Samsonoff WA, Chaturvedi S, Chaturvedi V. 2010. Extracellular fibrils of pathogenic yeastCryptococcus gattii are important for ecological niche, murine virulence and human neutrophil interactions. PLoS One 5:e10978. http://dx.doi.org/10.1371/journal.pone.0010978.
125. Escandon P, Quintero E, Granados D, Huerfano S, Ruiz A, Castaneda E. 2005. Isolation of Cryptococcus gattii serotype B from detritus of eucalyptus trees in Colombia. Biomedica (Bogota) 25:390–397.
126. Callejas A, Ordonez N, Rodriguez MC, Castaneda E. 1998. First isolation of Cryptococcus neoformans var. gattii, serotype C, from the environment in Colombia. Med. Mycol. 36:341–344. http://dx.doi.org/10.1046/j.1365-280X.1998.00159.x,http://dx.doi.org/10.1080/02681219880000531.
127. Springer DJ, Billmyre RB, Filler EE, Voelz K, Pursall R, Mieczkowski PA, Larsen RA, Dietrich FS, May RC, Filler SG, Heitman J. 2014. Cryptococcus gattiiVGIII isolates causing infectionsin HIV/AIDS patients inSouthern California: identification of the local environmental source as arboreal. PLoS Pathog. 10(8):e1004285. http://dx.doi.org/10.1371/journal.ppat.1004285.
128. Barreto de Oliveira MT, Boekhout T, Theelen B, Hagen F, Baroni FA, Lazera M., Lengeler KB, Heitman J, Rivera IN, Paula CR. 2004. Cryptococcus neoformans shows a remarkable genotypic diversity in Brazil. J. Clin. Microbiol. 42:1356–1359. http://dx.doi.org/10.1128/JCM.42.3.1356-1359.2004.
129. Chen S., Slavin MA, Heath CH, Playford EG, Byth K, Marriott D, Kidd SE, Bak N, Currie B, Hajkowicz K, Korman TM, McBride WJ, Meyer W, Murray R, Sorrell TC, Australia New Zealand Mycoses Interest Group-Cryptococcus Study. 2012. Clinical manifestations of Cryptococcus gattii infection: determinants of neurological sequelae and death. Clin. Infect. Dis. 55:789–798. http://dx.doi.org/10.1093/cid/cis529.
130. Galanis E, Hoang L, Kibsey P, Morshed M, Phillips P. 2009. Clinical presentation, diagnosis and management of Cryptococcus gattii cases: lessons learned from British Columbia. Can. J. Infect. Dis. Med. Microbiol. 20:23–28.
131. Harris J., Lockhart SR, Debess E, Marsden-Haug N, Goldoft M, Wohrle R, Lee S, Smelser C, Park B, Chiller T. 2011. Cryptococcus gattii in the United States: clinical aspects of infection with anemerging pathogen. Clin. Infect. Dis. 53:1188–1195. http://dx.doi.org/10.1093/cid/cir723.
132. Chaturvedi S, Dyavaiah M, Larsen RA, Chaturvedi V. 2005. Crypto-coccus gattii in AIDS patients, southern California. Emerg. Infect. Dis. 11:1686–1692. http://dx.doi.org/10.3201/eid1111.040875.
133. Bose I, Reese AJ, Ory JJ, Janbon G, Doering TL. 2003. A yeast under cover: the capsule ofCryptococcus neoformans. Eukaryot. Cell 2:655–663. http://dx.doi.org/10.1128/EC.2.4.655-663.2003.
134. Chen S., Wright L., Golding JC, Sorrell TC. 2000. Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans. Biochem. J. 347:431–439. http://dx.doi.org/10.1042/0264-6021:3470431.
135. Latouche GN, Sorrell TC, Meyer W. 2002. Isolation and characterisation of the phospholipase B gene of Cryptococcus neoformans var. gattii. FEMS Yeast Res. 2:551–561. http://dx.doi.org/10.1111/j.1567-1364.2002.tb00122.x.
136. Ngamskulrungroj P, Price J, Sorrell T, Perfect JR, Meyer W. 2011. Cryptococcus gattii virulence composite: candidate genes revealed by mi-croarray analysis of high and less virulent Vancouver Island outbreak strains. PLoS One 6:e16076. http://dx.doi.org/10.1371/journal.pone.0016076.
137. Moyrand F, Chang YC, Himmelreich U, Kwon-Chung KJ, Janbon G. 2004. Cas3p belongs to a seven-member family of capsule structure designer proteins. Eukaryot. Cell 3:1513–1524. http://dx.doi.org/10.1128/EC.3.6.1513-1524.2004.
138. Bahn YS, Jung KW. 2013. Stress signaling pathways for the pathogenic-ity of Cryptococcus. Eukaryot. Cell 12:1564–1577. http://dx.doi.org/10.1128/EC.00218-13.
139. Kronstad J., Attarian R, Cadieux B, Choi J, D’Souza CA, Griffiths EJ, Geddes JM, Hu G, Jung WH, Kretschmer M, Saikia S, Wang J. 2011. Expanding fungal pathogenesis: Cryptococcus breaks out of the opportunistic box. Nat. Rev. Microbiol. 9:193–203. http://dx.doi.org/10.1038/nrmicro2522.
140. Schneider RO, Fogaca NS, Kmetzsch L, Schrank A, Vainstein MH, Staats CC. 2012. Zap1 regulates zinc homeostasis and modulates virulence in Cryptococcus gattii. PLoS One 7:e43773. http://dx.doi.org/10.1371/journal.pone.0043773.
141. Ma H, May RC. 2009. Virulence in Cryptococcus species. Adv. Appl. Mi-crobiol. 67:131–190. http://dx.doi.org/10.1016/S0065-2164(08)01005-8.
142. Santangelo R, Zoellner H, Sorrell T, Wilson C, Donald C, Djordjevic J, Shounan Y, Wright L. 2004. Role of extracellular phospholipases and mononuclear phagocytes in dissemination of cryptococcosis in a murine model. Infect. Immun. 72:2229–2239. http://dx.doi.org/10.1128/IAI.72.4.2229-2239.2004.
143. Noverr MC, Williamson PR, Fajardo RS, Huffnagle GB. 2004. LAC1 is required for extrapulmonary dissemination of Cryptococcus neoformans but not pulmonary persistence. Infect. Immun. 72:1693–1699. http://dx.doi.org/10.1128/IAI.72.3.1693-1699.2004.
144. Olszewski MA, Noverr MC, Chen GH, Toews GB, Cox GM, Perfect JR, Huffnagle GB. 2004. Urease expression by Cryptococcus neoformans promotes microvascular sequestration, thereby enhancing central nervous system invasion. Am. J. Pathol. 164:1761–1771. http://dx.doi.org/10.1016/S0002-9440(10)63734-0.
145. Shi M, Li SS, Zheng C, Jones GJ, Kim KS, Zhou H, Kubes P, Mody CH. 2010. Real-time imaging of trapping and urease-dependent transmigration of Cryptococcus neoformans in mouse brain. J. Clin. Invest. 120: 1683–1693. http://dx.doi.org/10.1172/JCI41963.
146. Chayakulkeeree M, Johnston SA, Oei JB, Lev S, Williamson PR, Wilson CF, Zuo X, Leal AL, Vainstein MH, Meyer W, Sorrell TC, May RC, Djordjevic JT. 2011. SEC14 is a specific requirement for secretion of phospholipase B1 and pathogenicity of Cryptococcus neoformans. Mol. Microbiol. 80:1088–1101. http://dx.doi.org/10.1111/j.1365-2958.2011.07632.x.
147. Osterholzer JJ, Surana R, Milam JE, Montano GT, Chen GH, Sonstein J, Curtis JL, Huffnagle GB, Toews GB, Olszewski MA. 2009. Crypto-coccal urease promotes the accumulation of immature dendritic cells and a non-protective T2 immune response within the lung. Am. J. Pathol. 174:932–943. http://dx.doi.org/10.2353/ajpath.2009.080673.
148. Ma H, Hagen F, Stekel DJ, Johnston SA, Sionov E, Falk R, Polacheck I, Boekhout T, May RC. 2009. The fatal fungal outbreak on Vancouver Island is characterized by enhanced intracellular parasitism driven by mitochondrial regulation. Proc. Natl. Acad. Sci. U. S. A. 106:12980–12985. http://dx.doi.org/10.1073/pnas.0902963106.
149. Ngamskulrungroj P, Serena C, Gilgado F, Malik R, Meyer W. 2011. Global VGIIa isolates are of comparable virulence to the major fatal Cryptococcus gattii Vancouver Island outbreak genotype. Clin. Microbiol. Infect. 17:251–258. http://dx.doi.org/10.1111/j.1469-0691.2010.03222.x.
150. Tobin DM, May RC, Wheeler RT. 2012. Zebrafish: a see-through host and a fluorescent toolbox to probe host-pathogen interaction. PLoS Pat-hog. 8:e1002349. http://dx.doi.org/10.1371/journal.ppat.1002349.
151. Cheng PY, Sham A, Kronstad JW. 2009. Cryptococcus gattii isolates from the British Columbia cryptococcosis outbreak induce less protective inflammation in a murine model of infection than Cryptococcus neo-formans. Infect. Immun. 77:4284–4294. http://dx.doi.org/10.1128/IAI.00628-09.
152. Krockenberger MB, Malik R, Ngamskulrungroj P, Trilles L, Escandon P, Dowd S, Allen C, Himmelreich U, Canfield PJ, Sorrell TC, Meyer W. 2010. Pathogenesis of pulmonary Cryptococcus gattii infection: a rat model. Mycopathologia 170:315–330. http://dx.doi.org/10.1007/s11046-010-9328-z.
153. Chen S., Muller M, Zhou JZ, Wright L., Sorrell TC. 1997. Phospho-lipase activity in Cryptococcus neoformans: a new virulence factor? J. Infect. Dis. 175:414–420. http://dx.doi.org/10.1093/infdis/175.2.414.
154. Voelz K, Ma H, Phadke S, Byrnes EJ, Zhu P, Mueller O, Farrer RA, Henk DA, Lewit Y, Hsueh YP, Fisher MC, Idnurm A, Heitman J, May RC. 2013. Transmission of hypervirulence traits via sexual reproduction within and between lineages of the human fungal pathogen Cryptococcus gattii. PLoS Genet. 9:e1003771. http://dx.doi.org/10.1371/journal.pgen.1003771.
155. Chen YL, Lehman VN, Lewit Y, Averette AF, Heitman J. 2013. Cal-cineurin governs thermotolerance and virulence of Cryptococcus gattii. G3 3:527–539. http://dx.doi.org/10.1534/g3.112.004242.
156. Cutler JE. 1991. Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45:187–218. http://dx.doi.org/10.1146/annurev.mi.45.100191.001155.
157. Garcia-Solache MA, Izquierdo-Garcia D, Smith C, Bergman A, Casa-devall A. 2013. Fungal virulence in a lepidopteran model is an emergent property with deterministic features. mBio 4(3):e00100-13. http://dx.doi.org/10.1128/mBio.00100-13.
158. Perfect JR. 2012. The triple threat of cryptococcosis: it’s the body site, the strain, and/or the host. mBio 3(4):e00165-12. http://dx.doi.org/10.1128/mBio.00165-12.
159. Ngamskulrungroj P, Chang Y, Sionov E, Kwon-Chung KJ. 2012. The primary target organ of Cryptococcus gattii is different from that of Cryp-tococcus neoformans in a murine model. mBio 3(3):e00103-12. http://dx.doi.org/10.1128/mBio.00103-12.
160. Okubo Y, Tochigi N, Wakayama M, Shinozaki M, Nakayama H, Ishiwatari T, Shimodaira K, Nemoto T, Ohno H, Kaneko Y, Ma-kimura K, Uchida K, Miyazaki Y, Yamaguchi H, Shibuya K. 2013. How histopathology can contribute to an understanding of defense mechanisms against cryptococci. Mediators Inflamm. 2013:465319. http://dx.doi.org/10.1155/2013/465319.
161. Okubo Y, Wakayama M, Ohno H, Yamamoto S, Tochigi N, Tanabe K, Kaneko Y, Yamagoe S, Umeyama T, Shinozaki M, Nemoto T, Na-kayama H, Sasai D, Ishiwatari T, Shimodaira K, Yamamoto Y, Kamei K, Miyazaki Y, Shibuya K. 2013. Histopathological study of murine pulmonary cryptococcosis induced by Cryptococcus gattii and Cryptococ-cus neoformans. Jpn. J.Infect. Dis. 66:216–221. http://dx.doi.org/10.7883/yoken.66.216.
162. Wright L, Bubb W, Davidson J, Santangelo R, Krockenberger M, Himmelreich U, Sorrell TC. 2002. Metabolites released by Cryptococcus neoformans var. neoformans and var. gattii differentially affect human neutrophil function. Microbes Infect. 4:1427–1438. http://dx.doi.org/10.1016/S1286-4579(02)00024-2.
163. Huston SM, Mody CH. 2011. Cryptococcus interactions with innate cytotoxic lymphocytes, p 417–427. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.
164. Islam A, Li SS, Oykhman P, Timm-McCann M, Huston SM, Stack D, Xiang RF, Kelly MM, Mody CH. 2013. An acidic microenvironment increases NK cell killing of Cryptococcus neoformans and Cryptococcus gattii by enhancing perforin degranulation. PLoS Pathog. 9:e1003439. http://dx.doi.org/10.1371/journal.ppat.1003439.
165. Charlier C, Nielsen K, Daou S, Brigitte M, Chretien F, Dromer F. 2009. Evidence of a role for monocytes in dissemination and brain invasion by Cryptococcus neoformans. Infect. Immun. 77:120–127. http://dx.doi.org/10.1128/IAI.01065-08.
166. Huston SM, Li SS, Stack D, Timm-McCann M, Jones GJ, Islam A, Berenger BM, Xiang RF, Colarusso P, Mody CH. 2013. Cryptococcus gattii is killed by dendritic cells, but evades adaptive immunity by failing to induce dendritic cell maturation. J. Immunol. 191:249–261. http://dx.doi.org/10.4049/jimmunol.1202707.
167. Lester SJ, Malik R, Bartlett KH, Duncan CG. 2011. Cryptococcosis: update and emergence of Cryptococcus gattii. Vet. Clin. Pathol. 40:4–17. http://dx.doi.org/10.1111/j.1939-165X.2010.00281.x.
168. Trivedi SR, Malik R, Meyer W, Sykes JE. 2011. Feline cryptococcosis: impact of current research on clinical management. J. Feline Med. Surg. 13:163–172. http://dx.doi.org/10.1016/j.jfms.2011.01.009.
169. Sykes JE, Malik R. 2011. Cryptococcosis, p 621–634. In Greene CE (ed), Infectious diseases of the dog and cat. Elsevier Saunders, Philadelphia, PA.
170. Duncan C, Stephen C, Campbell J. 2006. Clinical characteristics and predictors of mortality for Cryptococcus gattii infection in dogs and cats of southwestern British Columbia. Can. Vet. J. 47:993–998.
171. Lester SJ, Kowalewich NJ, Bartlett KH, Krockenberger MB, Fairfax TM, Malik R. 2004. Clinicopathologic featuresof an unusual outbreak of cryptococcosis in dogs, cats, ferrets, and a bird: 38 cases (January to July 2003). J. Am. Vet. Med. Assoc. 225:1716–1722. http://dx.doi.org/10.2460/javma.2004.225.1716.
172. O’Brien CR, Krockenberger MB, Wigney DI, Martin P, Malik R. 2004. Retrospective study of feline and canine cryptococcosis in Australia from 1981 to 2001: 195 cases. Med. Mycol. 42:449–460. http://dx.doi.org/10.1080/13693780310001624547.
173. Connolly JH, Krockenberger MB, Malik R, Canfield PJ, Wigney DI, Muir DB. 1999. Asymptomatic carriage of Cryptococcus neoformans in the nasal cavity of the koala (Phascolarctos cinereus). Med. Mycol. 37: 331–338. http://dx.doi.org/10.1046/j.1365-280X.1999.00236.x.
174. McGill S, Malik R, Saul N, Beetson S, Secombe C, Robertson I, Irwin P. 2009. Cryptococcosis in domestic animals in Western Australia: a retrospective study from 1995-2006. Med. Mycol. 47:625–639. http://dx.doi.org/10.1080/13693780802512519.
175. Duncan C, Stephen C, Lester S, Bartlett KH. 2005. Follow-up study of dogs and cats with asymptomatic Cryptococcus gattii infection or nasal colonization. Med. Mycol. 43:663–666. http://dx.doi.org/10.1080/13693780500220076.
176. Kluger EK, Karaoglu HK, Krockenberger MB, Della Torre PK, Meyer W, Malik R. 2006. Recrudescent cryptococcosis, caused by Cryptococcus gattii (molecular type VGII), over a 13-year period in a Birman cat. Med. Mycol. 44:561–566. http://dx.doi.org/10.1080/13693780600582847.
177. Malik R, Wigney DI, Muir DB, Gregory DJ, Love DN. 1992. Crypto-coccosis in cats: clinical and mycological assessment of 29 cases and evaluation of treatment using orally administered fluconazole. J. Med. Vet. Mycol. 30:133–144. http://dx.doi.org/10.1080/02681219280000181.
178. Malik R, Martin P, Wigney DI, Church DB, Bradley W, Bellenger CR, Lamb WA, Barrs VR, Foster S, Hemsley S, Canfield PJ, Love DN. 1997. Nasopharyngeal cryptococcosis. Aust. Vet. J. 75:483–488. http://dx.doi.org/10.1111/j.1751-0813.1997.tb14377.x.
179. Barrs VR, Allan GS, Martin P, Beatty JA, Malik R. 2005. Feline pyothorax: a retrospective study of 27 cases in Australia. J. Feline Med. Surg. 7:211–222. http://dx.doi.org/10.1016/j.jfms.2004.12.004.
180. Sykes JE, Sturges BK, Cannon MS, Gericota B, Higgins RJ, Trivedi SR, Dickinson PJ, Vernau KM, Meyer W, Wisner ER. 2010. Clinical signs, imaging features, neuropathology, and outcome in cats and dogs with central nervous system cryptococcosis from California. J. Vet. Intern. Med. 24: 1427–1438. http://dx.doi.org/10.1111/j.1939-1676.2010.0633.x.
181. Berthiaume DR, Kline KL. 2012. What is your neurologic diagnosis? C. gattii infection.J.Am. Vet. Med. Assoc. 241:1437–1439. http://dx.doi.org/10.2460/javma.241.11.1437.
182. Duncan CG, Stephen C, Campbell J. 2006. Evaluation of risk factors for Cryptococcus gattii infection in dogs and cats. J. Am. Vet. Med. Assoc. 228:377–382. http://dx.doi.org/10.2460/javma.228.3.377.
183. Malik R, Dill-Macky E, Martin P, Wigney DI, Muir DB, Love DN. 1995. Cryptococcosis in dogs: a retrospective study of 20 consecutive cases. J. Med. Vet. Mycol. 33:291–297. http://dx.doi.org/10.1080/02681219580000601.
184. Bowles DB, Fry DR. 2009. Nasal cryptococcosis in two dogs in New Zealand. N. Z. Vet. J. 57:53–57. http://dx.doi.org/10.1080/00480169.2009.36869.
185. Backhouse TC, Bolliger A. 1960. Cryptococcosis in the koala Phascolar-ctos cinereus. Aust. J. Sci. 23:86–87.
186. Krockenberger MB, Canfield PJ, Malik R. 2003. Cryptococcus neofor-mans var. gattii in the koala (Phascolarctos cinereus): a review of 43 cases of cryptococcosis. Med. Mycol. 41:225–234. http://dx.doi.org/10.1080/369378031000137242.
187. Krockenberger MB, Canfield PJ, Barnes J, Vogelnest L, Connolly J, Ley C, Malik R. 2002. Cryptococcus neoformans var. gattii in the koala (Phascolarctos cinereus): serological evidence for subclinical cryptococ-cosis. Med. Mycol. 40:273–282. http://dx.doi.org/10.1080/mmy.40.3.273.282.
188. Krockenberger MB, Canfield PJ, Malik R. 2002. Cryptococcus neofor-mans in the koala (Phascolarctos cinereus): colonization by C. n. var. gattii and investigation of environmental sources. Med. Mycol. 40:263–272. http://dx.doi.org/10.1080/mmy.40.3.263.272.
189. Kido N, Makimura K, Kamegaya C, Shindo I, Shibata E, Omiya T, Yamamoto Y. 2012. Long-term surveillance and treatment of subclinical cryptococcosis and nasal colonization byCryptococcus neoformansand C. gattii species complex in captive koalas (Phascolarctes cinereus). Med. Mycol. 50:291–298. http://dx.doi.org/10.3109/13693786.2011.594967.
190. Malik R, Krockenberger MB, Cross G, Doneley R, Madill DN, Black D, McWhirter P, Rozenwax A, Rose K, Alley M, Forshaw D, Russell-Brown I, Johnstone AC, Martin P, O’Brien CR, Love DN. 2003. Avian cryptococcosis. Med. Mycol. 41:115–124. http://dx.doi.org/10.1080/mmy.41.2.115.124.
191. Morera N, Juan-Salles C, Torres JM, Andreu M, Sanchez M, Zamora MA, Colom MF. 2011. Cryptococcus gattii infection in a Spanish pet ferret (Mustela putorius furo) and asymptomatic carriage in ferrets and humans from its environment. Med. Mycol. 49:779–784. http://dx.doi.org/10.3109/13693786.2011.564216.
192. Malik R, Alderton B, Finlaison D, Krockenberger MB, Karaoglu H, Meyer W, Martin P, France MP, McGill J, Lester SJ, O’Brien CR, Love DN. 2002. Cryptococcosis in ferrets: a diverse spectrum of clinical disease. Aust. Vet. J. 80:749–755. http://dx.doi.org/10.1111/j.1751-0813.2002.tb11343.x.
193. Miller WG, Padhye AA, van Bonn W, Jensen E, Brandt ME, Ridgway SH. 2002. Cryptococcosis in a bottlenose dolphin (Tursiops truncatus) caused by Cryptococcus neoformans var. gattii. J. Clin. Microbiol. 40:721–724. http://dx.doi.org/10.1128/JCM.40.2.721-724.2002.
194. Norman SA, Raverty S, Zabek E, Etheridge S, Ford JK, Hoang L., Morshed M. 2011. Maternal-fetal transmission of Cryptococcus gattii in harbor porpoise. Emerg. Infect. Dis. 17:304–305. http://dx.doi.org/10.3201/eid1702.101232.
195. Tintelnot K, Lemmer K, Losert H, Schar G, Polak A. 2004. Follow-up of epidemiological data of cryptococcosis in Austria, Germany and Switzerland with special focus on the characterization of clinical isolates. Mycoses 47: 455–464. http://dx.doi.org/10.1111/j.1439-0507.2004.01072.x.
196. Datta K, Bartlett KH, Baer R, Byrnes E, Galanis E, Heitman J, Hoang L, Leslie MJ, MacDougall L, Magill SS, Morshed M., Marr K., Cryptococcus gattii Working Group of the Pacific Northwest. 2009. Spread of Cryptococcus gattii into Pacific Northwest region of the United States. Emerg. Infect. Dis. 15:1185–1191. http://dx.doi.org/10.3201/eid1508.081384.
197. Galanis E, MacDougall L, Kidd S, Morshed M, British Columbia Cryptococcus gattii Working Group. 2010. Epidemiology of Cryptococ-cus gattii, British Columbia, Canada, 1999-2007. Emerg. Infect. Dis. 16: 251–257. http://dx.doi.org/10.3201/eid1602.090900.
198. Gatti F, Eeckels R. 1970. An atypical strain of Cryptococcus neoformans (San Felice) Vuillemin 1894. I. Description of the disease and of the strain. Ann. Soc. Belges Med. Trop. Parasitol. Mycol. 50:689–693.
199. Slobodniuk R, Naraqi S. 1980. Cryptococcal meningitis in the central province of Papua New Guinea. P. N. G. Med. J. 23:111–116.
200. Lehmann PF, Morgan RJ, Freimer EH. 1984. Infection with Cryptococ-cus neoformans var. gattii leading to a pulmonary cryptococcoma and meningitis. J. Infect. Dis. 9:301–306.
201. Kohl KH, Hof H, Schrettenbrunner A, Seeliger HP, Kwon-Chung KJ. 1985. Cryptococcus neoformans var. gattii in Europe. Lancet i:1515.
202. Dromer F, Ronin O, Dupont B. 1992. Isolation of Cryptococcus neofor-mans var. gattii from an Asian patient in France: evidence for dormant infection in healthy subjects. J. Med. Vet. Mycol. 30:395–397. http://dx.doi.org/10.1080/02681219280000511.
203. Fisher D, Burrow J, Lo D, Currie B. 1993. Cryptococcus neoformans in tropical northern Australia: predominantly variant gattii with good outcomes. Aust. N. Z. J. Med. 23:678–682. http://dx.doi.org/10.1111/j.1445-5994.1993.tb04726.x.
204. Mitchell DH, Sorrell TC. 1992. Pancoast’s syndrome due to pulmonary infection with Cryptococcus neoformans var. gattii. Clin. Infect. Dis. 14: 1142–1144. http://dx.doi.org/10.1093/clinids/14.5.1142.
205. Rozenbaum R, Goncalves AJ. 1994. Clinical epidemiological study of 171 cases of cryptococcosis. Clin. Infect. Dis. 18:369–380. http://dx.doi.org/10.1093/clinids/18.3.369.
206. Lopez-Martinez R, Soto-Hernandez JL, Ostrosky-Zeichner L, Cas-tanon-Olivares LR, Angeles-Morales V, Sotelo J. 1996. Cryptococcus neoformans var. gattii among patients with cryptococcal meningitis in Mexico. First observations. Mycopathologia 134:61–64.
207. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. 1997. Visual loss in immunocompetent patients with Cryptococcus neoformans var. gattiimeningitis. Trans. R. Soc. Trop. Med. Hyg. 91:44–49. http://dx.doi.org/10.1016/S0035-9203(97)90391-6.
208. Seaton RA, Hamilton AJ, Hay RJ, Warrell DA. 1996. Exposure to Cryptococcus neoformans var. gattii—a seroepidemiological study. Trans. R. Soc. Trop. Med. Hyg. 90:508–512. http://dx.doi.org/10.1016/S0035-9203(96)90297-7.
209. Seaton RA, Naraqi S, Wembri JP, Warrell DA. 1996. Predictors of outcome in Cryptococcus neoformans var. gattii meningitis. QJM 89:423–428. http://dx.doi.org/10.1093/qjmed/89.6.423.
210. Lalloo D, Fisher D, Naraqi S, Laurenson I, Temu P, Sinha A, Saweri A, Mavo B. 1994. Cryptococcal meningitis (C. neoformans var. gattii) leading to blindness in previously healthy Melanesian adults in Papua New Guinea. QJM 87:343–349.
211. Laurenson I, Naraqi S, Howcroft N, Burrows I, Saulei S. 1993. Cryp-tococcal meningitis in Papua New Guinea: ecology and the role of euca-lypts. Med. J. Aust. 158:213.
212. Laurenson IF, Trevett AJ, Lalloo DG, Nwokolo N, Naraqi S, Black J, Tefurani N, Saweri A, Mavo B, Igo J, Warrell DA. 1996. Meningitis caused by Cryptococcus neoformans var. gattii and var. neoformans in Papua New Guinea. Trans. R. Soc. Trop. Med. Hyg. 90:57–60. http://dx.doi.org/10.1016/S0035-9203(96)90479-4.
213. Laurenson IF, Lalloo DG, Naraqi S, Seaton RA, Trevett AJ, Matuka A, Kevau IH. 1997. Cryptococcus neoformans in Papua New Guinea: a common pathogen but an elusive source. J. Med. Vet. Mycol. 35:437–440. http://dx.doi.org/10.1080/02681219780001561.
214. Jenney A, Pandithage K, Fisher DA, Currie BJ. 2004. Cryptococcus infection in tropical Australia. J. Clin. Microbiol. 42:3865–3868. http://dx.doi.org/10.1128/JCM.42.8.3865-3868.2004.
215. Lane M, McBride J, Archer J. 2004. Steroid responsive late deterioration in Cryptococcus neoformansvar.gattiimeningitis. Neurology 63:713–714. http://dx.doi.org/10.1212/01.WNL.0000134677.29120.62.
216. Einsiedel L, Gordon DL, Dyer JR. 2004. Paradoxical inflammatory reaction during treatment of Cryptococcus neoformans var. gattii meningitis in an HIV-seronegative woman. Clin. Infect. Dis. 39:e78–e82. http://dx.doi.org/10.1086/424746.
217. Laman M, Hwaihwanje I, Davis TM, Manning L. 2010. Cryptococcal meningitis in immunocompetent Papua New Guinean children. Trop. Doct. 40:61–63. http://dx.doi.org/10.1258/td.2009.090333.
218. Correa MP, Oliveira EC, Duarte RR, Pardal PP, Oliveira FM, Severo LC. 1999. Cryptococcosis in children in the State of Para, Brazil. Rev. Soc. Bras. Med. Trop. 32:505–508. http://dx.doi.org/10.1590/S0037-86821999000500006.
219. Correa MP, Severo LC, Oliveira FM, Irion K, Londero AT. 2002. The spectrum of computerized tomography (CT) findings in central nervous system (CNS) infection due to Cryptococcus neoformans var. gattii in immunocompetent children. Rev. Inst. Med. Trop. Sao Paulo 44:283–287. http://dx.doi.org/10.1590/S0036-46652002000500010.
220. Martins LM, Wanke B, Lazera M., Trilles L, Barbosa GG, Macedo RC, Cavalcanti MA, Eulalio KD, Castro JA, Silva AS, Nascimento FF, Gouveia VA, Monte SJ. 2011. Genotypes of Cryptococcus neoformans and Cryptococcus gattii as agents of endemic cryptococcosis in Teresina, Piaui (northeastern Brazil). Mem. Inst. Oswaldo Cruz 106:725–730. http://dx.doi.org/10.1590/S0074-02762011000600012.
221. dos Santos WR, Meyer W, Wanke B, Costa SP, Trilles L, Nascimento JL, Medeiros R, Morales BP, Bezzera CC, Macêdo RC, Ferriera SO, Barbosa GG, Perez MA, Nishikawa MM, Lazéra MS. 2008. Primary endemic Cryptococcus gattii molecular type VGII in the state of Brasil. Mem. Inst. Oswaldo Cruz 103:813–818. http://dx.doi.org/10.1590/S0074-02762008000800012.
222. Pinto Junior VL, Pone MV, Pone SM, Campos JM, Garrido JR, de Barros AC, Trilles L, Barbosa GG, Morales BP, Bezerra CC, Lazera MS. 2010. Cryptococcus gattii molecular type VGII as agent of meningitis in a healthy child in Rio de Janeiro, Brazil: report of an autochthonous case. Rev. Soc. Bras. Med. Trop. 43:746–748. http://dx.doi.org/10.1590/S0037-86822010000600032.
223. Mora DJ, Pedrosa AL, Rodrigues V, Leite Maffei CM, Trilles L, Dos Santos Lazera M, Silva-Vergara ML. 2010. Genotype and mating type distribution within clinical Cryptococcus neoformans and Cryptococcus gattii isolates from patients with cryptococcal meningitis in Uberaba, Minas Gerais, Brazil. Med. Mycol. 48:561–569. http://dx.doi.org/10.3109/13693780903358317.
224. Grosse P, Tintelnot K, Sollner O, Schmitz B. 2001. Encephalomyelitis due to Cryptococcus neoformans var. gattii presenting as spinal tumour: case report and review of the literature. J. Neurol. Neurosurg. Psychiatr. 70:113–116. http://dx.doi.org/10.1136/jnnp.70.1.113.
225. Taylor MB, Chadwick D, Barkham T. 2002. First reported isolation of Cryptococcus neoformans var. gattii from a patient in Singapore. J. Clin. Microbiol. 40:3098–3099. http://dx.doi.org/10.1128/JCM.40.8.3098-3099.2002.
226. Koh TH, Tan AL, Lo YL, Oh H. 2002. Cryptococcus neoformans var. gattii meningitis in Singapore. Med. Mycol. 40:221–223. http://dx.doi.org/10.1080/mmy.40.2.221.223.
227. Lingegowda BP, Koh TH, Ong HS, Tan TT. 2011. Primary cutaneous cryptococcosis due to Cryptococcus gattii in Singapore. Singapore Med. J. 52:e160–e162.
228. MacDougall L, Fyfe M. 2006. Emergence of Cryptococcus gattii in a novel environment provides clues to its incubation period. J. Clin. Microbiol. 44:1851–1852. http://dx.doi.org/10.1128/JCM.44.5.1851-1852.2006.
229. MacDougall L, Fyfe M, Romney M, Starr M, Galanis E. 2011. Risk factors for Cryptococcus gattii infection, British Columbia, Canada. Emerg. Infect. Dis. 17:193–199. http://dx.doi.org/10.3201/eid1702.101020.
230. Garrett L, Marr K, West S, Allada G. 2011. 74-year-old man from the Pacific Northwest with fever and a lung mass. Chest 140:814–817. http://dx.doi.org/10.1378/chest.10-2964.
231. Meiring ST, Quan VC, Cohen C, Dawood H, Karstaedt AS, McCarthy KM, Whitelaw AC, Govender NP, Group for Enteric, Respiratory and Meningeal Disease Surveillance in South Africa. 2012. A comparison of cases of paediatric-onset and adult-onset cryptococcosis detected through population-based surveillance, 2005-2007. AIDS 26:2307–2314. http://dx.doi.org/10.1097/QAD.0b013e3283570567.
232. Araujo BS, Bay M, Reichert R, Goldani LZ. 2012. Intra-abdominal cryptococcosis by Cryptococcus gattii: case report and review. Myco-pathologia 174:81–85. http://dx.doi.org/10.1007/s11046-011-9517-4.
233. Mistry N, Tan K, Shokravi M, Hoang L. 2011. Cryptococcus gattii infections with cutaneous involvement. J. Cutan. Med. Surg. 15:236–237.
234. Hamann ID, Gillespie RJ, Ferguson JK. 1997. Primary cryptococcal cellulitis caused by Cryptococcus neoformans var. gattii in an immuno-competent host. Australas. J. Dermatol. 38:29–32. http://dx.doi.org/10.1111/j.1440-0960.1997.tb01095.x.
235. Bellissimo-Rodrigues F, Baciotti M, Zanatto MP, Silva JO, Martins MA, Martinez R. 2010. Cutaneous cryptococcosis due to Cryptococcus gattii in a patient on chronic corticotherapy. Rev. Soc. Bras. Med. Trop. 43:211–212. http://dx.doi.org/10.1590/S0037-86822010000200022.
236. Dewar GJ, Kelly JK. 2008. Cryptococcus gattii: an emerging cause of pulmonary nodules. Can. Respir. J. 15:153–157.
237. Hagen F, van Assen S, Luijckx GJ, Boekhout T, Kampinga GA. 2010. Activated dormant Cryptococcus gattii infection in a Dutch tourist who visited Vancouver Island (Canada): a molecular epidemiologi-cal approach. Med. Mycol. 48:528–531. http://dx.doi.org/10.3109/13693780903300319.
238. Chau TT, Mai NH, Phu NH, Nghia HD, Chuong LV, Sinh DX, Duong VA, Diep PT, Campbell J., Baker S, Hien TT, Lalloo DG, Farrar JJ, Day JN. 2010. A prospective descriptive study of cryptococcal meningitis in HIV uninfected patients inVietnam—high prevalence ofCryptococcus neoformans var. grubii in the absence of underlying disease. BMC Infect. Dis. 10:199. http://dx.doi.org/10.1186/1471-2334-10-199.
239. Upton A, Fraser JA, Kidd SE, Bretz C, Bartlett KH, Heitman J, Marr KA. 2007. First contemporary case of human infection with Cryptococcus gattii in Puget Sound: evidence for spread of the Vancouver Island outbreak. J. Clin. Microbiol. 45:3086–3088. http://dx.doi.org/10.1128/JCM.00593-07.
240. Phillips P, Chapman K, Sharp M, Harrison P, Vortel J, Steiner T, Bowie W. 2009. Dexamethasone in Cryptococcus gattii central nervous system infection. Clin. Infect. Dis. 49:591–595. http://dx.doi.org/10.1086/603554.
241. Byrnes EJ, III, Li W, Lewit Y, Perfect JR, Carter D., Cox GM, Heitman J. 2009. First reported case of Cryptococcus gattii in the Southeastern USA: implications for travel-associated acquisition of an emerging pathogen. PLoS One 4:e5851. http://dx.doi.org/10.1371/journal.pone.0005851.
242. McCulloh RJ, Phillips R, Perfect JR, Byrnes EJ, III, Heitman J, Dufort E. 2011. Cryptococcus gattii genotype VGI infection in New England. Pediatr. Infect. Dis. J. 30:1111–1114. http://dx.doi.org/10.1097/INF.0b013e31822d14fd.
243. Nagarathna S, Kumari HB, Arvind N, Divyalakshmi A, Chandramuki A, Satishchandra P, Ravi V. 2010. Prevalence of Cryptococcus gattii causing meningitisinatertiary neurocare center from south India:a pilot study. Ind. J. Pathol. Microbiol. 53:855–856. http://dx.doi.org/10.4103/0377-4929.72001.
244. Iatta R, Hagen F, Fico C, Lopatriello N, Boekhout T, Montagna MT. 2012. Cryptococcus gattii infection inan immunocompetent patient from southern Italy. Mycopathologia 174:87–92. http://dx.doi.org/10.1007/s11046-011-9493-8.
245. Tsunemi T, Kamata T, Fumimura Y, Watanabe M, Yamawaki M, Saito Y, Kanda T, Ohashi K, Suegara N, Murayama S, Makimura K, Yama-guchi H, Mizusawa H. 2001. Immunohistochemical diagnosis of Cryp-tococcus neoformans var. gattii infection in chronic meningoencephalitis: the first case in Japan. Intern. Med. 40:1241–1244. http://dx.doi.org/10.2169/internalmedicine.40.1241.
246. Sellers B, Hall P, Cine-Gowdie S, Hays AL, Patel K, Lockhart SR, Franco-Paredes C. 2012. Cryptococcus gattii: an emerging fungal pathogen in the Southeastern United States. Am. J. Med. Sci. 343:510–511. http://dx.doi.org/10.1097/MAJ.0b013e3182464bc7.
247. Hasimoto e Souza LK, Costa CR, Fernandes OFL, Abrao FY, Silva TC, Tremea CM, Silva MR. 2013. Clinical and microbiological features of cryptococcal meningitis. Rev. Soc. Bras. Med. Trop. 46:343–347. http://dx.doi.org/10.1590/0037-8682-0061-2012.
248. Okamoto K, Hatakeyama S, Itoyama S, Nukui Y, Yoshino Y, Kitazawa T, Yotsuyanagi H, Ikeda R, Sugita T, Koike K. 2010. Cryptococcus gattii genotype VGIIa infection in man, Japan, 2007. Emerg. Infect. Dis. 16: 1155–1157. http://dx.doi.org/10.3201/eid1607.100106.
249. Johannson KA, Huston SM, Mody CH, Davidson W. 2012. Cryptococ-cus gattii pneumonia. CMAJ 184:1387–1390. http://dx.doi.org/10.1503/cmaj.111346.
250. Harris J., Lockhart SR, Sondermeyer G, Vugia DJ, Crist MB, D’Angelo MT, Sellers B, Franco-Paredes C, Makvandi M, Smelser C, Greene J, Stanek D, Signs K, Nett RJ, Chiller T, Park BJ. 2013. Cryptococcus gattii infections in multiple states outside the US Pacific Northwest. Emerg. Infect. Dis. 19:1620–1626.
251. Centers for Disease Control and Prevention. 2010. Emergence of Cryp-tococcus gattii—Pacific Northwest, 2004-2010. MMWR Morb. Mortal. Wkly. Rep. 59:865–868.
252. Kunadharaju R, Choe U, Harris J., Lockhart SR, Greene JN. 2013. Cryptococcus gattii, Florida, USA, 2011. Emerg. Infect. Dis. 19:519–521. http://dx.doi.org/10.3201/eid1903.121399.
253. Sorrell TC. 2001. Cryptococcus neoformans variety gattii. Med. Mycol. 39:155–168. http://dx.doi.org/10.1080/mmy.39.2.155.168.
254. Sorrell TC, Chen SCA, Phillips P, Marr K. 2011. Clinical perspectives on Cryptococcus neoformans and Cryptococcus gattii: implications for diagnosis and management, p 595–606. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from pathogen to model yeast. ASM Press, Washington, DC.
255. Severo CB, Xavier MO, Gazzoni AF, Severo LC. 2009. Cryptococcosis in children. Paediatr. Respir. Rev. 10:166–171. http://dx.doi.org/10.1016/j.prrv.2009.06.009.
256. Harris J, Lockhart S, Chiller T. 2012. Cryptococcus gattii: where do we go from here? Med. Mycol. 50:113–129. http://dx.doi.org/10.3109/13693786.2011.607854.
257. Marr KA. 2012. Cryptococcus gattii as an important fungal pathogen of western North America. Expert Rev. Anti Infect. Ther. 10:637–643. http://dx.doi.org/10.1586/eri.12.48.
258. Bartlett K, Byrnes E, Duncan C, Fyfe M, Galanis E, Heitman J, Hoand L, Kidd S, MacDougall L, Mak S, Marr K, Moshed M, West S, Kronstad J. 2011. The emergence of Cryptococcus gattii infections on Vancouver Island and expansion in the Pacific Northwest, p 313–325. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from pathogen to model yeast. ASM Press, Washington, DC.
259. Pukkila-Worley R, Mylonakis E. 2008. Epidemiology and management of cryptococcal meningitis: developments and challenges. Expert Opin. Pharmacother. 9:551–560. http://dx.doi.org/10.1517/14656566.9.4.551.
260. Banerjee U, Datta K, Majumdar T, Gupta K. 2001. Cryptococcosis in India: the awakening of a giant? Med. Mycol. 39:51–67. http://dx.doi.org/10.1080/mmy.39.1.51.67.
261. McMullan BJ, Sorell TC, Chen SCA. 2013. Cryptococcus gattii infections: contemporary aspects of epidemiology, clinical manifestations and management of infection. Future Microbiol. 8:1613–1631. http://dx.doi.org/10.2217/fmb.13.123.
262. Pappas PG. 2013. Cryptococcal infections in non-HIV-infected patients. Trans. Am. Clin. Climatol. Assoc. 124:61–79.
263. Bartlett KH, Cheng PY, Duncan C, Galanis E, Hoang L, Kidd S, Lee MK, Lester S, MacDougall L, Mak S, Morshed M, Taylor M, Kronstad J. 2012. A decade of experience: Cryptococcus gattii in British Columbia. Myco-pathologia 173:311–319. http://dx.doi.org/10.1007/s11046-011-9475-x.
264. Chaturvedi V, Chaturvedi S. 2011. Cryptococcus gattii: a resurgent fungal pathogen. Trends Microbiol. 19:564–571. http://dx.doi.org/10.1016/j.tim.2011.07.010.
265. Howell SA. 2011. Candida, Cryptococcus, and other yeasts of medical importance, p 1793–1821. In Versalovic J, Carroll KC, Guido F, Jor-gensen JH, Landry ML, Warnock DW (ed), Manual of clinical microbiology, 19th ed. ASM Press, Washington, DC.
266. Currie B, Vigus T, Leach G, Dwyer B. 1990. Cryptococcus neoformans var. gattii. Lancet 336:1442. http://dx.doi.org/10.1016/0140-6736(90)93137-E.
267. Speed BR, Kaldor J. 1997. Rarity of cryptococcal infection in children. Pediatr. Infect. Dis. J. 16:536–537. http://dx.doi.org/10.1097/00006454-199705000-00024.
268. Brandt ME, Hutwagner LC, Klug LA, Baughman WS, Rimland D, Graviss EA, Hamill RJ, Thomas C, Pappas PG, Reingold AL, Pinner RW, Cryptococcal Disease Active Surveillance Group. 1996. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States. J. Clin. Microbiol. 34:912–917.
269. BC Center for Disease Control. 2011. British Columbia annual summary of reportable disease. BC Center for Disease Control, Vancouver, BC, Canada.
270. Iverson SA, Chiller T, Beekmann S, Polgreen PM, Harris J. 2012. Recognition and diagnosis of Cryptococcus gattii infections in the United States. Emerg. Infect. Dis. 18:1012–1015. http://dx.doi.org/10.3201/eid1806.111228.
271. Walraven CJ, Gerstein W, Hardison SE, Wormley F, Lockhart SR, Harris J., Fothergill A, Wickes B, Gober-Wilcox J, Massie L, Ku TS, Firacative C, Meyer W, Lee SA. 2011. Fatal disseminated Cryptococcus gattii infection in New Mexico. PLoS One 6:e28625. http://dx.doi.org/10.1371/journal.pone.0028625.
272. Ellis D, Pfeiffer T. 1994. Cryptococcosis and the ecology of Cryptococcus neoformans. Jpn. J. Med. Mycol. 35:111–122. http://dx.doi.org/10.3314/jjmm.35.111.
273. Montenegro H, Paula CR. 2000. Environmental isolation of Cryptococ-cus neoformans var. gattii and C. neoformansvar. neoformans in the city of Sao Paulo, Brazil. Med. Mycol. 38:385–390. http://dx.doi.org/10.1080/mmy.38.5.385.390.
274. Van Dam MG, Seaton RA, Hamilton AJ. 1998. Analysis of HLA association in susceptibility to infection with Cryptococcus neoformans var. gattii in a Papua New Guinean population. Med. Mycol. 36:185–188. http://dx.doi.org/10.1080/02681219880000281.
275. Rosen LB, Freeman AF, Yang LM, Jutivorakool K, Olivier KN, Ang-kasekwinai N, Suputtamongkol Y, Bennett JE, Pyrgos V, Williamson PR, Ding L, Holland SM, Browne SK. 2013. Anti-GM-CSF autoanti-bodies in patients with cryptococcal meningitis. J. Immunol. 190:3959–3966. http://dx.doi.org/10.4049/jimmunol.1202526.
276. Kampitak T, Suwanpimolkul G, Browne S, Suankratay C. 2011. Anti-interferon-gamma autoantibody and opportunistic infections: case series and review of the literature. Infection 39:65–71. http://dx.doi.org/10.1007/s15010-010-0067-3.
277. Browne SK, Burbelo PD, Chetchotisakd P, Suputtamongkol Y, Kier-tiburanakul S, Shaw PA, Kirk JL, Jutivorakool K, Zaman R, Ding L, Hsu AP, Patel SY, Olivier KN, Lulitanond V, Mootsikapun P, Anun-natsiri S, Angkasekwinai N, Sathapatayavongs B, Hsueh PR, Shieh CC, Brown MR, Thongnoppakhun W, Claypool R, Sampaio EP, Thepthai C, Waywa D, Dacombe C, Reizes Y, Zelazny AM, Saleeb P, Rosen LB, Mo A, Iadarola M, Holland SM. 2012. Adult-onset immunodeficiency in Thailand and Taiwan. N. Engl. J. Med. 367:725–734. http://dx.doi.org/10.1056/NEJMoa1111160.
278. Saijo T, Chen J, Chen S., Rosen LB, Yi J, Sorrell TC, Bennett JE, Holland SM, Browne SK, Kwon-Chung KJ. 2014. Anti-granulocyte-macrophage colony-stimulating factor autoantibodies are a risk factor for central nervous system infection by Cryptococcus gattii in otherwise immunocompetent patients. mBio 5(2):e00912-14. http://dx.doi.org/10.1128/mBio.00912-14.
279. Marr K., Datta K, Pirofski LA, Barnes R. 2012. Cryptococcus gattii infection in healthy hosts: a sentinel for subclinical immunodeficiency? Clin. Infect. Dis. 54:153–154. http://dx.doi.org/10.1093/cid/cir756.
280. Zonios DI, Falloon J, Huang CY, Chaitt D, Bennett JE. 2007. Crypto-coccosis and idiopathic CD4 lymphocytopenia. Medicine 86:78–92. http://dx.doi.org/10.1097/md.0b013e31803b52f5.
281. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50:291–322. http://dx.doi.org/10.1086/649858.
282. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:E66. http://dx.doi.org/10.1542/peds.107.5.e66.
283. Pappalardo MC, Melhem MS. 2003. Cryptococcosis: a review of the Brazilian experience for the disease. Rev. Inst. Med. Trop. Sao Paulo 45:299–305. http://dx.doi.org/10.1590/S0036-46652003000600001.
284. Garcia-Hermoso D, Janbon G, Dromer F. 1999. Epidemiological evidence for dormant Cryptococcus neoformansinfection.J. Clin. Microbiol. 37:3204–3209.
285. Dromer F, Casadevall A, Perfect JR, Sorrell TC. 2011. Cryptococcus neoformans: latency and disease, p 431–439. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from pathogen to model yeast. ASM Press, Washington, DC.
286. Dora JM, Kelbert S, Deutschendorf C, Cunha VS, Aquino VR, Santos RP, Goldani LZ. 2006. Cutaneous cryptococccosis due to Cryptococcus gattii in immunocompetent hosts: case report and review. Mycopatho-logia 161:235–238. http://dx.doi.org/10.1007/s11046-006-0277-5.
287. Lacaz CS, Heins-Vaccari EM, Hernandez-Arriagada GL, Martins EL, Prearo CA, Corim SM, Martins MA. 2002. Primary cutaneous crypto-coccosis due to Cryptococcus neoformans var. gattii serotype B, in an im-munocompetent patient. Rev. Inst. Med. Trop. Sao Paulo 44:225–228. http://dx.doi.org/10.1590/S0036-46652002000400008.
288. Leao CA, Ferreira-Paim K, Andrade-Silva L, Mora DJ, da Silva PR, Machado AS, Neves PF, Pena GS, Teixeira LS, Silva-Vergara ML. 2011. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in an immunocompetent host. Med. Mycol. 49:352–355. http://dx.doi.org/10.3109/13693786.2010.530697.
289. Tilak R, Prakash P, Nigam C, Tilak V, Gambhir IS, Gulati AK. 2009. Cryptococcal meningitis with an antecedent cutaneous cryptococcal lesion. Dermatol. Online J. 15:12.
290. Rex JH, Larsen RA, Dismukes WE, Cloud GA, Bennett JE. 1993. Catastrophic visual loss due to Cryptococcus neoformans meningitis. Medicine 72:207–224.
291. Andreola C, Ribeiro MP, de Carli CR, Gouvea AL, Curi AL. 2006. Multifocal choroiditis in disseminated Cryptococcus neoformans infection. Am. J. Ophthalmol. 142:346–348. http://dx.doi.org/10.1016/j.ajo.2006.03.024.
292. Kestelyn P, Taelman H, Bogaerts J, Kagame A, Abdel Aziz M, Batung-wanayo J, Stevens AM, Van de Perre P. 1993. Ophthalmic manifestations of infections with Cryptococcus neoformans in patients with the acquired immunodeficiency syndrome. Am. J. Ophthalmol. 116:721–727.
293. Graybill JR, Sobel J, Saag M, van Der Horst C, Powderly W, Cloud G, Riser L, Hamill R, Dismukes W, NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. 2000. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryp-tococcal meningitis. Clin. Infect. Dis. 30:47–54. http://dx.doi.org/10.1086/313603.
294. Johnston SR, Corbett EL, Foster O, Ash S, Cohen J. 1992. Raised intracranial pressure and visual complications in AIDS patients with cryptococcal meningitis. J. Infect. 24:185–189. http://dx.doi.org/10.1016/0163-4453(92)92954-H.
295. Park MK, Hospenthal DR, Bennett JE. 1999. Treatment of hydroceph-alus secondary to cryptococcal meningitis by use of shunting. Clin. Infect. Dis. 28:629–633. http://dx.doi.org/10.1086/515161.
296. Liliang PC, Liang CL, Chang WN, Chen HJ, Su TM, Lu K, Lu CH. 2003. Shunt surgery for hydrocephalus complicating cryptococcal meningitis in human immunodeficiency virus-negative patients. Clin. Infect. Dis. 37:673–678. http://dx.doi.org/10.1086/377208.
297. Haddow LJ, Colebunders R, Meintjes G, Lawn SD, Elliott JH, Manabe YC, Bohjanen PR, Sungkanuparph S, Easterbrook PJ, French MA, Boulware DR, International Network for the Study of HIV-Associated IRIS. 2010. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect. Dis. 10:791–802. http://dx.doi.org/10.1016/S1473-3099(10)70170-5.
298. Chen SCA, Korman TM, Slavin MA, Marriott D, Byth K, Bak N, Currie B., Hajkowicz K, Heath CH, Kidd S, McBride WJ, Meyer W, Murray R, Playford EG, Sorrell TC, Australia New Zealand Mycoses Interest Group Cryptococcus Study. 2013. Antifungal therapy and management of complicationsof cryptococcosis due to Cryptococcus gat-tii. Clin. Infect. Dis. 57:543–551. http://dx.doi.org/10.1093/cid/cit341.
299. Boulware DR, Bonham SC, Meya DB, Wiesner DL, Park GS, Kam-bugu A, Janoff EN, Bohjanen PR. 2010. Paucity of initial cerebrospinal fluid inflammation in cryptococcal meningitis is associated with subsequent immune reconstitution inflammatory syndrome. J. Infect. Dis. 202:962–970. http://dx.doi.org/10.1086/655785.
300. Longley N, Harrison TS, Jarvis JN. 2013. Cryptococcal immune recon-stitution inflammatory syndrome. Curr. Opin. Infect. Dis. 26:26–34. http://dx.doi.org/10.1097/QCO.0b013e32835c21d1.
301. Boulware DR, Meya DB, Bergemann TL, Wiesner DL, Rhein J, Mu-subire A, Lee SJ, Kambugu A, Janoff EN, Bohjanen PR. 2010. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med. 7:e1000384. http://dx.doi.org/10.1371/journal.pmed.1000384.
302. Wiesner DL, Boulware DR. 2011. Cryptococcus-related immune recon-stitution inflammatory syndrome (IRIS): pathogenesis and its clinical implications. Curr. Fungal Infect. Rep. 5:252–261. http://dx.doi.org/10.1007/s12281-011-0064-8.
303. Wiesner DL, Moskalenko O, Corcoran JM, McDonald T, Rolfes MA, Meya DB, Kajumbula H, Kambugu A, Bohjanen PR, Knight JF, Boulware DR, Nielsen K. 2012. Cryptococcal genotype influences im-munologic response and human clinical outcome after meningitis. mBio 3(5):e00196-12. http://dx.doi.org/10.1128/mBio.00196-12.
304. Dromer F, Mathoulin-Pélissier S, Launay O, Lortholary O, French Cryptococcosis Study Group. 2007. Determinants of disease presentation and outcome during cryptococcosis: the Crypto A/D study. PLoS Med. 4(2):e21. http://dx.doi.org/10.1371/journal.pmed.0040021.
305. Ostrow TD, Hudgins PA. 1994. Magnetic resonance imaging of intra-cranial fungal infections. Top. Magn. Reson. Imaging 6:22–31.
306. Smith AB, Smirniotopoulos JG, Rushing EJ. 2008. Central nervous system infections associated with human immunodeficiency virus infection: radiologic-pathologic correlation. Radiographics 28:2033–2058. http://dx.doi.org/10.1148/rg.287085135.
307. Sorrell TC, Himmelreich U. 2008. NMR in mycology. Curr. Fungal Infect. Rep. 2:149–156. http://dx.doi.org/10.1007/s12281-008-0022-2.
308. Himmelreich U, Dzendrowskyj TE, Allen C, Dowd S, Malik R, Shehan BP, Russell P, Mountford CE, Sorrell TC. 2001. Cryptococcomas distinguished from gliomas with MR spectroscopy: an experimental rat and cell culture study. Radiology 220:122–128. http://dx.doi.org/10.1148/radiology.220.1.r01jl25122.
309. Himmelreich U, Allen C, Dowd S, Malik R, Shehan BP, Mountford C, Sorrell TC. 2003. Identification of metabolites of importance in the pathogenesis of pulmonary cryptococcoma using nuclear magnetic resonance spectroscopy. Microbes Infect. 5:285–290. http://dx.doi.org/10.1016/S1286-4579(03)00028-5.
310. Dzendrowskyj TE, Dolenko B, Sorrell TC, Somorjai RL, Malik R, Mountford CE, Himmelreich U. 2005. Diagnosis of cerebral cryptococ-coma using a computerized analysis of 1H NMR spectra in an animal model. Diagn. Microbiol. Infect. Dis. 52:101–105. http://dx.doi.org/10.1016/j.diagmicrobio.2005.02.004.
311. Diaz M., Nguyen MH. 2011. Diagnostic approach based on capsular antigen, capsule detection, B-glucan and DNA analysis, p 547–564. In Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, Casadevall A (ed), Cryptococcus: from human pathogen to model yeast. ASM Press, Washington, DC.
312. Saha DC, Xess I, Jain N. 2008. Evaluation of conventional & serological methods for rapid diagnosis of cryptococcosis. Indian J. Med. Res. 127: 483–488.
313. Petter R, Kang BS, Boekhout T, Davis BJ, Kwon-Chung KJ. 2001. A survey of heterobasidiomycetous yeasts for the presence of the genes homologous to virulence factors of Filobasidiella neoformans, LAC1 and CAP59. Microbiology 147:2029–2036.
314. Okoli I, Oyeka CA, Kwon-Chung KJ, Theelen B, Robert V, Groe-newald JZ, McFadden DC, Casadevall A, Boekhout T. 2007. Crypto-trichosporon anacardii gen. nov., sp. nov., a new trichosporonoid capsu-late basidiomycetous yeast from Nigeria that is able to form melanin on niger seed agar. FEMS Yeast Res. 7:339–350. http://dx.doi.org/10.1111/j.1567-1364.2006.00164.x.
315. Suwantarat N, Watkins T, Lee R, Carroll KC. 2014. False-positive reaction of L-canavanine glycine bromothymol blue medium with Candida famata. J.Clin. Microbiol. 52:1308–1309. http://dx.doi.org/10.1128/JCM.00149-14.
316. Currie B., Freundlich LF, Soto MA, Casadevall A. 1993. False-negative cerebrospinal fluid cryptococcal latex agglutination tests for patients with culture-positive cryptococcal meningitis. J. Clin. Microbiol. 31: 2519–2522.
317. Heelan JS, Corpus L, Kessimian N. 1991. False-positive reactions in the latex agglutination test for Cryptococcus neoformans antigen. J. Clin. Mi-crobiol. 29:1260–1261.
318. Hamilton JR, Noble A, Denning DW, Stevens DA. 1991. Performance of cryptococcus antigen latex agglutination kits on serum and cerebro-spinal fluid specimens of AIDS patients before and after pronase treatment. J. Clin. Microbiol. 29:333–339.
319. Engler HD, Shea YR. 1994. Effect of potential interference factors on performance of enzyme immunoassay and latex agglutination assay for cryptococcal antigen. J. Clin. Microbiol. 32:2307–2308.
320. Liaw YS, Yang PC, Yu CJ, Chang DB, Wang HJ, Lee LN, Kuo SH, Luh KT. 1995. Direct determination of cryptococcal antigen in transthoracic needle aspirate for diagnosis of pulmonary cryptococcosis. J. Clin. Mi-crobiol. 33:1588–1591.
321. Chapin-Robertson K, Bechtel C, Waycott S, Kontnick C, Edberg SC. 1993. Cryptococcal antigen detection from the urine of AIDS patients. Diagn. Microbiol. Infect. Dis. 17:197–201. http://dx.doi.org/10.1016/0732-8893(93)90096-P.
322. Kralovic SM, Rhodes JC. 1998. Utility of routine testing of bronchoal-veolar lavage fluid for cryptococcal antigen. J. Clin. Microbiol. 36:3088–3089.
323. Hansen J, Slechta ES, Gates-Hollingsworth MA, Neary B, Barker AP, Bauman S, Kozel TR, Hanson KE. 2013. Large-scale evaluation of the Immuno-Mycologics lateral flow and enzyme-linked immunoassays for detection of cryptococcal antigen in serum and cerebrospinal fluid. Clin. Vaccine Immunol. 20:52–55. http://dx.doi.org/10.1128/CVI.00536-12.
324. McMullan BJ, Halliday C, Sorrell TC, Judd D, Sleiman S, Marriott D, Olma T, Chen SCA. 2012. Clinical utility of the cryptococcal antigen lateral flow assay in a diagnostic mycology laboratory. PLoS One 7:e49541. http://dx.doi.org/10.1371/journal.pone.0049541.
325. Jarvis JN, Percival A, Bauman S, Pelfrey J, Meintjes G, Williams GN, Longley N, Harrison TS, Kozel TR. 2011. Evaluation of a novel pointof-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 53: 1019–1023. http://dx.doi.org/10.1093/cid/cir613.
326. Lindsley MD, Mekha N, Baggett HC, Surinthong Y, Autthateinchai R, Sawatwong P, Harris J., Park BJ, Chiller T, Balajee SA, Poonwan N. 2011. Evaluation of a newly developed lateral flow immunoassay for the diagnosis of cryptococcosis. Clin. Infect. Dis. 53:321–325. http://dx.doi.org/10.1093/cid/cir379.
327. Kabanda T, Siedner MJ, Klausner JD, Muzoora C, Boulware DR. 2014. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin. Infect. Dis. 58:113–116. http://dx.doi.org/10.1093/cid/cit641.
328. Rajasingham R, Meya DB, Boulware DR. 2012. Integrating cryptococcal antigen screening and pre-emptive treatment into routine HIV care. J. Acquir. Immune Defic. Syndr. 59:e85–e91. http://dx.doi.org/10.1097/QAI.0b013e31824c837e.
329. Brouwer AE, Teparrukkul P, Pinpraphaporn S, Larsen RA, Chierakul W, Peacock S, Day N, White NJ, Harrison TS. 2005. Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis. J. Infect. Dis. 192: 681–684. http://dx.doi.org/10.1086/432073.
330. Rajasingham R, Boulware DR. 2012. Reconsidering cryptococcal antigen screening in the U.S. among persons with CD4 < 100 cells/mcL. Clin. Infect. Dis. 55:1742–1744. http://dx.doi.org/10.1093/cid/cis725.
331. Sidrim JJ, Costa AK, Cordeiro RA, Brilhante RS, Moura FE, Castelo-Branco DS, Neto MP, Rocha MF. 2010. Molecular methods for the diagnosis and characterization of Cryptococcus: a review. Can. J. Microbiol. 56:445–458. http://dx.doi.org/10.1139/W10-030.
332. Paschoal RC, Hirata MH, Hirata RC, Melhem MS, Dias AL, Paula CR. 2004. Neurocryptococcosis: diagnosis by PCR method. Rev. Inst. Med. Trop. Sao Paulo 46203–207. http://dx.doi.org/10.1590/S0036-46652004000400006.
333. Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, Halliday C. 2007. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J. Clin. Microbiol. 45:380–385. http://dx.doi.org/10.1128/JCM.01862-06.
334. Pryce TM, Palladino S, Kay ID, Coombs GW. 2003. Rapid identification of fungi by sequencing the ITS1 and ITS2 regions using an automated capillary electrophoresis system. Med. Mycol. 41:369–381. http://dx.doi.org/10.1080/13693780310001600435.
335. Rappelli P, Are R, Casu G, Fiori PL, Cappuccinelli P, Aceti A. 1998. Development of a nested PCR for detection of Cryptococcus neoformans in cerebrospinal fluid. J. Clin. Microbiol. 36:3438–3440.
336. Bialek R, Weiss M, Bekure-Nemariam K, Najvar LK, Alberdi MB, Gray-bill JR, Reischl U. 2002. Detection of Cryptococcus neoformans DNA in tissue samples by nested and real-time PCR assays. Clin. Diagn. Lab. Immunol. 9:461–469. http://dx.doi.org/10.1128/CDLI.9.2.461-469.2002.
337. Zou CC, Yu ZS, Tang LF, Liang L, Zhao ZY. 2006. Primary abdominal lymphonodular cryptococcosis in children: 2 case reports and a literature review. J. Pediatr. Surg. 41:e11–e15. http://dx.doi.org/10.1016/j.jpedsurg.2005.11.083.
338. Levy PY, Habib G, Reynaud-Gaubert M, Raoult D, Rolain JM. 2008. Pericardial effusion due to Cryptococcus neoformans in a patient with cystic fibrosis following lung transplantation. Int. J. Infect. Dis. 12:452. http://dx.doi.org/10.1016/j.ijid.2007.12.001.
339. Veron V, Simon S, Blanchet D, Aznar C. 2009. Real-time polymerase chain reaction detection of Cryptococcus neoformans and Cryptococcus gattii in human samples. Diagn. Microbiol. Infect. Dis. 65:69–72. http://dx.doi.org/10.1016/j.diagmicrobio.2009.05.005.
340. Katsu M, Kidd S, Ando A, Moretti-Branchini ML, Mikami Y, Nishimura K, Meyer W. 2004. The internal transcribed spacers and 5.8S rRNA gene show extensive diversity among isolates of the Cryptococcus neoformans species complex. FEMS Yeast Res. 4:377–388. http://dx.doi.org/10.1016/S1567-1356(03)00176-4.
341. Chen YC, Eisner JD, Kattar MM, Rassoulian-Barrett SL, Lafe K, Bui U, Limaye AP, Cookson BT. 2001. Polymorphic internal transcribed spacer region 1 DNA sequences identify medically important yeasts. J. Clin. Microbiol. 39: 4042–4051. http://dx.doi.org/10.1128/JCM.39.11.4042-4051.2001.
342. Leal AL, Faganello J, Bassanesi MC, Vainstein MH. 2008. Cryptococcus species identification by multiplex PCR. Med. Mycol. 46:377–383. http://dx.doi.org/10.1080/13693780701824429.
343. Esposto MC, Cogliati M, Tortorano AM, Viviani MA. 2004. Determination of Cryptococcus neoformans var. neoformans mating type by multiplex PCR. Clin. Microbiol. Infect. 10:1092–1094. http://dx.doi.org/10.1111/j.1469-0691.2004.00972.x.
344. Carvalho VG, Terceti MS, Dias AL, Paula CR, Lyon JP, de Siqueira AM, Franco MC. 2007. Serotype and mating type characterization of Cryptococcus neoformans by multiplex PCR. Rev. Soc. Bras. Med. Trop. 49:207–210. http://dx.doi.org/10.1590/S0036-46652007000400002.
345. Feng X, Fu X, Ling B, Wang L, Liao W, Yao Z. 2013. Development of a singleplex PCR assay for rapid identification and differentiation of Cryptococcus neoformans var.grubii,Cryptococcus neoformansvar. neofor-mans, Cryptococcus gattii, and hybrids. J. Clin. Microbiol. 51:1920–1923. http://dx.doi.org/10.1128/JCM.00064-13.
346. Kaocharoen S, Wang B, Tsui KM, Trilles L, Kong F, Meyer W. 2008. Hyperbranched rolling circle amplification as a rapid and sensitive method for species identification within the Cryptococcus species complex. Electro-phoresis 29:3183–3191. http://dx.doi.org/10.1002/elps.200700903.
347. Demidov VV.2002. Rolling-circle amplification inDNA diagnostics: the power of simplicity. Expert Rev. Mol. Diagn. 2:542–548. http://dx.doi.org/10.1586/14737159.2.6.542.
348. Zhou X, Kong F, Sorrell TC, Wang H, Duan Y, Chen SCA. 2008. Practical method for detection and identification ofCandida,Aspergillus, and Scedosporium spp. by use of rolling-circle amplification. J. Clin. Mi-crobiol. 46:2423–2427. http://dx.doi.org/10.1128/JCM.00420-08.
349. Diaz M., Boekhout T, Kiesling T, Fell JW. 2005. Comparative analysis of the intergenic spacer regions and population structure of the species complex of the pathogenic yeast Cryptococcus neoformans. FEMS Yeast Res. 5:1129–1140. http://dx.doi.org/10.1016/j.femsyr.2005.05.005.
350. Bovers M, Diaz M., Hagen F, Spanjaard L, Duim B, Visser CE, Hoogveld HL, Scharringa J, Hoepelman IM, Fell JW, Boekhout T. 2007. Identification of genotypically diverse Cryptococcus neoformans and Cryptococcus gattii isolates by Luminex xMAP technology. J. Clin. Microbiol. 45:1874–1883. http://dx.doi.org/10.1128/JCM.00223-07.
351. McTaggart LR, Lei E, Richardson SE, Hoang L, Fothergill A, Zhang SX. 2011. Rapid identification of Cryptococcus neoformans and Crypto-coccus gattii by matrix-assisted laser desorption ionization–time of flight mass spectrometry. J. Clin. Microbiol. 49:3050–3053. http://dx.doi.org/10.1128/JCM.00651-11.
352. Clark AE, Kaleta EJ, Arora A, Wolk DM. 2013. Matrix-assisted laser desorption ionization–time of flight mass spectrometry: a fundamental shift in the routine practice of clinical microbiology. Clin. Microbiol. Rev. 26:547–603. http://dx.doi.org/10.1128/CMR.00072-12.
353. Pinto A, Halliday C, Zahra M, van Hal S, Olma T, Maszewska K, Iredell JR, Meyer W, Chen SCA. 2011. Matrix-assisted laser desorption ionization-time of flight mass spectrometry identification of yeasts is contingent on robust reference spectra. PLoS One 6:e25712. http://dx.doi.org/10.1371/journal.pone.0025712.
354. Calderaro A, Martinelli M, Motta F, Larini S, Arcangeletti MC, Medici MC, Chezzi C, De Conto F. 2014. Comparison of peptide nucleic acid fluorescence in situ hybridization assays with culture-based matrix-assisted laser desorption/ionization-time of flight mass spectrometry for the identification of bacteria and yeasts from blood cultures and cerebro-spinal fluid cultures. Clin. Microbiol. Infect. 20:O468–O475. http://dx.doi.org/10.1111/1469-0691.12490.
355. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, CLSI document M27–A3. Clinical and Laboratory Standards Institute, Wayne, PA.
356. Espinel-Ingroff A, Chowdhary A, Cuenca-Estrella M, Fothergill A, Fuller J, Hagen F, Govender N, Guarro J, Johnson E, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, Trilles L, Kidd S, Turnidge J. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility end-point distributions and epidemiological cutoff values for amphoteri-cin B and flucytosine. Antimicrob. Agents Chemother. 56:3107–3113. http://dx.doi.org/10.1128/AAC.06252-11.
357. Espinel-Ingroff A, Aller AI, Canton E, Castanon-Olivares LR, Chow-dhary A, Cordoba S, Cuenca-Estrella M, Fothergill A, Fuller J, Gov-ender N, Hagen F, Illnait-Zaragozi MT, Johnson E, Kidd S, Lass-Florl C, Lockhart SR, Martins MA, Meis JF, Melhem MS, Ostrosky-Zeichner L, Pelaez T, Pfaller MA, Schell WA, St-Germain G, Trilles L, Turnidge J. 2012. Cryptococcus neoformans-Cryptococcus gattii species complex: an international study of wild-type susceptibility endpoint distributions and epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole. Antimicrob. Agents Chemother. 56:5898–5906. http://dx.doi.org/10.1128/AAC.01115-12.
358. Lockhart SR, Iqbal N, Bolden CB, DeBess EE, Marsden-Haug N, Worhle R, Thakur R, Harris J., Cryptococcus gattii PNW Public Health Working Group. 2012. Epidemiologic cutoff values for triazole drugs in Cryptococcus gattii: correlation of molecular type and in vitro susceptibility. Diagn. Microbiol. Infect. Dis. 73:144–148. http://dx.doi.org/10.1016/j.diagmicrobio.2012.02.018.
359. Pfaller MA, Castanheira M, Diekema DJ, Messer SA, Jones RN. 2011. Wild-type MIC distributions and epidemiologic cutoff values for flu-conazole, posaconazole, and voriconazole when testing Cryptococcus neoformans as determined by the CLSI broth microdilution method. Di-agn. Microbiol. Infect. Dis. 71:252–259. http://dx.doi.org/10.1016/j.diagmicrobio.2011.07.007.
360. Pfaller MA, Castanheira M, Messer SA, Moet GJ, Jones RN. 2011. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009). Diagn. Microbiol. Infect. Dis. 69:45–50. http://dx.doi.org/10.1016/j.diagmicrobio.2010.08.013.
361. Ellis D, Sorrell T, Chen S. 2007. Impact of antifungal resistance in Australia. Microbiol. Aust. 28:171–173.
362. Thompson GR, Wiederhold NP, Fothergill AW, Vallor AC, Wickes BL, Patterson TF. 2009. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans. Antimicrob. Agents Chemother. 53:309–311. http://dx.doi.org/10.1128/AAC.01216-08.
363. Pfaller MA, Messer SA, Boyken L, Rice C, Tendolkar S, Hollis RJ, Doern GV, Diekema DJ. 2005. Global trends in the antifungal susceptibility of Cryptococcus neoformans (1990 to 2004). J. Clin. Microbiol. 43:2163–2167. http://dx.doi.org/10.1128/JCM.43.5.2163-2167.2005.
364. Tay ST, Tanty Haryanty T, Ng KP, Rohani MY, Hamimah H. 2006. In vitro susceptibilities of Malaysian clinical isolates of Cryptococcus neofor-mans var. grubii and Cryptococcus gattii to five antifungal drugs. Mycoses 49:324–330. http://dx.doi.org/10.1111/j.1439-0507.2006.01242.x.
365. Thompson GR, Fothergill AW, Wiederhold NP, Vallor AC, Wickes BL, Patterson TF. 2008. Evaluation of Etest method for determining isavuconazole MICs against Cryptococcus gattii and Cryptococcus neofor-mans. Antimicrob. Agents Chemother. 52:2959–2961. http://dx.doi.org/10.1128/AAC.00646-08.
366. Chowdhary A, Randhawa HS, Sundar G, Kathuria S, Prakash A, Khan Z, Sun S, Xu J. 2011. In vitro antifungal susceptibility profiles and genotypesof308 clinical and environmental isolates of Cryptococcus neo-formans var. grubii and Cryptococcus gattii serotype B from northwestern India. J. Med. Microbiol. 60:961–967. http://dx.doi.org/10.1099/jmm.0.029025-0.
367. Torres-Rodriguez JM, Alvarado-Ramirez E, Murciano F, Sellart M. 2008. MICs and minimum fungicidal concentrations of posacona-zole, voriconazole and fluconazole for Cryptococcus neoformans and Cryptococcus gattii. Antimicrob. Agents Chemother. 62:205–206. http://dx.doi.org/10.1093/jac/dkn132.
368. Andrade-Silva L, Ferreira-Paim K, Mora DJ, Da Silva PR, Andrade AA, Araujo NE, Pedrosa AL, Silva-Vergara ML. 2013. Susceptibility profile of clinical and environmental isolates of Cryptococcus neoformans and Cryptococcus gattii in Uberaba, Minas Gerais, Brazil. Med. Mycol. 51:635–640. http://dx.doi.org/10.3109/13693786.2012.761737.
369. Trilles L, Fernandez-Torres B, Lazera M., Wanke B, Guarro J. 2004. In vitro antifungal susceptibility of Cryptococcus gattii. J. Clin. Microbiol. 42:4815–4817. http://dx.doi.org/10.1128/JCM.42.10.4815-4817.2004.
370. Iqbal N, DeBess EE, Wohrle R, Sun B, Nett RJ, Ahlquist AM, Chiller T, Lockhart SR, Cryptococcus gattii Public Health Working Group. 2010. Correlation ofgenotype andin vitrosusceptibilities of Cryptococcus gattii strains from the Pacific Northwest of the United States. J. Clin. Microbiol. 48:539–544. http://dx.doi.org/10.1128/JCM.01505-09.
371. Trilles L, Meyer W, Wanke B, Guarro J, Lazera M. 2012. Correlation of antifungal susceptibility and molecular type within the Cryptococcus neoformans/C. gattii species complex. Med. Mycol. 50:328–332. http://dx.doi.org/10.3109/13693786.2011.602126.
372. Hagen F, Illnait-Zaragozi MT, Bartlett KH, Swinne D, Geertsen E, Klaassen CH, Boekhout T, Meis JF. 2010. In vitro antifungal susceptibilities and amplified fragment length polymorphism genotyping of a worldwide collection of 350 clinical, veterinary, and environmental Cryptococcus gattii isolates. Antimicrob. Agents Chemother. 54:5139–5145. http://dx.doi.org/10.1128/AAC.00746-10.
373. Datta K, Rhee P, Byrnes E III, Garcia-Effron G, Perlin DS, Staab JF, Marr KA. 2013. Isavuconazole activity against Aspergillus lentulus, Neo-sartorya udagawae, and Cryptococcus gattii, emerging fungal pathogens with reduced azole susceptibility. J. Clin. Microbiol. 51:3090–3093. http://dx.doi.org/10.1128/JCM.01190-13.
374. Chong HS, Dagg R, Malik R, Chen S, Carter D. 2010. In vitro susceptibility ofthe yeast pathogenCryptococcustofluconazole and other azoles varies with molecular genotype. J. Clin. Microbiol. 48:4115–4120. http://dx.doi.org/10.1128/JCM.01271-10.
375. Morales BP, Neves Junior I, Trilles L, Bertho AL, Oliveira RD, Ni-shikawa MM, Elias MD, Wanke B, Lazera MD. 2014. Determination of the minimum inhibitory concentration of Cryptococcus neoformans and Cryptococcus gattii against fluconazole by flow cytometry. Med. Mycol. 52:90–98. http://dx.doi.org/10.3109/13693786.2013.806827.
376. Rodero L, Mellado E, Rodriguez AC, Salve A, Guelfand L, Cahn P, Cuenca-Estrella M, Davel G, Rodriguez-Tudela JL. 2003. G484S amino acid substitution in lanosterol 14-alpha demethylase (ERG11) is related to fluconazole resistance in a recurrent Cryptococcus neoformans clinical isolate. Antimicrob. Agents Chemother. 47:3653–3656. http://dx.doi.org/10.1128/AAC.47.11.3653-3656.2003.
377. Sionov E, Lee H, Chang YC, Kwon-Chung KJ. 2010. Cryptococcus neoformans overcomes stress of azole drugs by formation of disomy in specific multiple chromosomes. PLoS Pathog. 6:e1000848. http://dx.doi.org/10.1371/journal.ppat.1000848.
378. Morschhauser J. 2002. The genetic basis of fluconazole resistance development in Candida albicans. Biochim. Biophys. Acta 1587:240–248. http://dx.doi.org/10.1016/S0925-4439(02)00087-X.
379. Sanguinetti M, Posteraro B, La Sorda M, Torelli R, Fiori B, Santangelo R, Delogu G, Fadda G. 2006. Role of AFR1, an ABC transporter-encoding gene, in the in vivo response to fluconazole and virulence of Cryptococcus neoformans. Infect. Immun. 74:1352–1359. http://dx.doi.org/10.1128/IAI.74.2.1352-1359.2006.
380. Gast CE, Basso LR Jr, Bruzual I, Wong B. 2013. Azole resistance in Cryptococcus gattiifrom the Pacific Northwest: investigationof the role of ERG11. Antimicrob. Agents Chemother. 57:5478–5485. http://dx.doi.org/10.1128/AAC.02287-12.
381. Cannon RD, Lamping E, Holmes AR, Niimi K, Baret PV, Keniya MV, Tanabe K, Niimi M, Goffeau A, Monk BC. 2009. Efflux-mediated antifungal drug resistance. Clin. Microbiol. Rev. 22:291–321. http://dx.doi.org/10.1128/CMR.00051-08.
382. Posteraro B, Sanguinetti M, Sanglard D, La Sorda M, Boccia S, Romano L, Morace G, Fadda G. 2003. Identification and characterization of a Cryptococ-cus neoformans ATP binding cassette (ABC) transporter-encoding gene, CnAFR1, involved in the resistance to fluconazole. Mol. Microbiol. 47: 357–371. http://dx.doi.org/10.1046/j.1365-2958.2003.03281.x.
383. Mondon P, Petter R, Amalfitano G, Luzzati R, Concia E, Polacheck I, Kwon-Chung KJ. 1999. Heteroresistance to fluconazole and voriconazole in Cryptococcus neoformans. Antimicrob. Agents Chemother. 43:1856–1861.
384. Sionov E, Chang YC, Garraffo HM, Kwon-Chung KJ. 2009. Heterore-sistance to fluconazole in Cryptococcus neoformans is intrinsic and associated with virulence. Antimicrob. Agents Chemother. 53:2804–2815. http://dx.doi.org/10.1128/AAC.00295-09.
385. Chen S, Marr K., Sorrell TC. 2013. Cryptococcus gattii infection— treatment. In Kauffman CA (ed), UpToDate. UpToDate, Inc, Waltham, MA. http://www.uptodate.com/contents/cryptococcus-gattii-infection -treatment.
386. Seaton RA, Verma N, Naraqi S, Wembri JP, Warrell DA. 1997. The effect of corticosteroids on visual loss in Cryptococcus neoformans var. gattii meningitis. Trans. R. Soc. Trop. Med. Hyg. 91:50–52. http://dx.doi.org/10.1016/S0035-9203(97)90393-X.
387. Chen S, Marr K., Sorrell TC. 2013. Cryptococcus gattii infection: clinical features and diagnosis.In Basow DS (ed), UpToDate. UpToDate, Inc, Waltham, MA.
388. Bolton LA, Lobetti RG, Evezard DN, Picard JA, Nesbit JW, van Heerden J, Burroughs RE. 1999. Cryptococcosis in captive cheetah (Acinonyx jubatus): two cases. J. S. Afr. Vet. Assoc. 70:35–39.
389. Narasipura SD, Ault JG, Behr MJ, Chaturvedi V, Chaturvedi S. 2003. Characterization of Cu,Zn superoxide dismutase (SOD1) gene knockout mutant of Cryptococcus neoformans var. gattii: role in biology and virulence. Mol. Microbiol. 47:1681–1694. http://dx.doi.org/10.1046/j.1365-2958.2003.03393.x.
390. Narasipura SD, Chaturvedi V, Chaturvedi S. 2005. Characterization of Cryptococcus neoformans var. gattii SOD2 reveals distinct roles of the two superoxide dismutases in fungal biology and virulence. Mol. Microbiol. 55:1782–1800. http://dx.doi.org/10.1111/j.1365-2958.2005.04503.x.
391. Petzold EW, Himmelreich U, Mylonakis E, Rude T, Toffaletti D, Cox GM, Miller JL, Perfect JR. 2006. Characterization and regulation of the trehalose synthesis pathway and its importance in the pathogenicity of Cryptococcus neoformans. Infect. Immun. 74:5877–5887. http://dx.doi.org/10.1128/IAI.00624-06.
392. Ngamskulrungroj P, Himmelreich U, Breger JA, Wilson C, Chayakul-keeree M, Krockenberger MB, Malik R, Daniel HM, Toffaletti D, Djordjevic JT, Mylonakis E, Meyer W, Perfect JR. 2009. The trehalose synthesis pathway is an integral part of the virulence composite for Cryp-tococcus gattii. Infect. Immun. 77:4584–4596. http://dx.doi.org/10.1128/IAI.00565-09.
393. D’Souza CA, Alspaugh JA, Yue C, Harashima T, Cox GM, Perfect JR, Heitman J. 2001. Cyclic AMP-dependent protein kinase controls virulence of the fungal pathogen Cryptococcus neoformans. Mol. Cell. Biol. 21:3179–3191. http://dx.doi.org/10.1128/MCB.21.9.3179-3191.2001.
394. Hicks JK, Heitman J. 2007. Divergence of protein kinase A catalytic subunits in Cryptococcus neoformans and Cryptococcus gattii illustrates evolutionary reconfiguration of a signaling cascade. Eukaryot. Cell 6:413–420. http://dx.doi.org/10.1128/EC.00213-06.
395. Chayakulkeeree M, Sorrell TC, Siafakas AR, Wilson CF, Pantarat N, Gerik KJ, Boadle R, Djordjevic JT. 2008. Role and mechanism of phos-phatidylinositol-specific phospholipase C in survival and virulence of Cryptococcus neoformans. Mol. Microbiol. 69:809–826. http://dx.doi.org/10.1111/j.1365-2958.2008.06310.x.
396. Kraus PR, Fox DS, Cox GM, Heitman J. 2003. The Cryptococcus neoformans MAP kinase Mpk1 regulates cell integrity in response to an-tifungal drugs and lossof calcineurin function. Mol. Microbiol. 48:1377–1387. http://dx.doi.org/10.1046/j.1365-2958.2003.03508.x.
397. Ren P, Springer DJ, Behr MJ, Samsonoff WA, Chaturvedi S, Chatur-vedi V. 2006. Transcription factor STE12alpha has distinct roles in morphogenesis, virulence, and ecological fitness of the primary pathogenic yeast Cryptococcus gattii. Eukaryot. Cell 5:1065–1080. http://dx.doi.org/10.1128/EC.00009-06.
398. Yue C, Cavallo LM, Alspaugh JA, Wang P, Cox GM, Perfect JR, Heitman J. 1999. The STE12alpha homolog is required for haploid fila-mentation but largely dispensable for mating and virulence in Cryptococ-cus neoformans. Genetics 153:1601–1615.
399. Ngamskulrungroj P, Chang Y, Roh J, Kwon-Chung KJ. 2012. Differences in nitrogen metabolism between Cryptococcus neoformans and C. gattii, the two etiologic agents of cryptococcosis. PLoS One 7:e34258. http://dx.doi.org/10.1371/journal.pone.0034258.
400. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. EMBO J. 16:2576–2589. http://dx.doi.org/10.1093/emboj/16.10.2576.
401. Cruz MC, Sia RA, Olson M, Cox GM, Heitman J. 2000. Comparison of the roles of calcineurin in physiology and virulence in serotype D and serotype A strains of Cryptococcus neoformans. Infect. Immun. 68:982–985. http://dx.doi.org/10.1128/IAI.68.2.982-985.2000.
402. Calvo BM, Colombo AL, Fischman O, Santiago A, Thompson L, Lazera M, Telles F, Fukushima K, Nishimura K, Tanaka R, Myiajy M, Moretti-Branchini ML. 2001. Antifungal susceptibilities, varieties, and electrophoretic karyotypes of clinical isolates of Cryptococcus neoformans from Brazil, Chile, and Venezuela. J. Clin. Microbiol. 39:2348–2350. http://dx.doi.org/10.1128/JCM.39.6.2348-2350.2001.
403. Gomez-Lopez A, Zaragoza O, Dos Anjos Martins M, Melhem MC, Rodriguez-Tudela JL, Cuenca-Estrella M. 2008. In vitro susceptibility of Cryptococcus gattii clinical isolates. Clin. Microbiol. Infect. 14:727–730. http://dx.doi.org/10.1111/j.1469-0691.2008.02021.x.
404. Matos CS, de Souza Andrade A, Oliveira NS, Barros TF. 2012. Microbiological characteristics of clinical isolates of Cryptococcus spp. in Bahia, Brazil: molecular types and antifungal susceptibilities. Eur. J. Clin. Mi-crobiol. Infect. Dis. 31:1647–1652. http://dx.doi.org/10.1007/s10096-011-1488-3.
405. Silva DC, Martins MA, Szeszs MW, Bonfietti LX, Matos D, Melhem MS. 2012. Susceptibility to antifungal agents and genotypes of Brazilian clinical and environmental Cryptococcus gattii strains. Diagn. Microbiol. Infect. Dis. 72:332–339. http://dx.doi.org/10.1016/j.diagmicrobio.2011.11.016.
406. Zhu P, Zhai B, Lin X, Idnurm A. 2013. Congenic strains for genetic analysis of virulence traits in Cryptococcus gattii. Infect. Immun. 81: 2616–2625. http://dx.doi.org/10.1128/IAI.00018-13.